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INTRODUCTION 
 
  ""PØ£zøu ²shõÀ Põ¯® AÈ¯õx 
  PØ£zvÚõ÷»  Põn»õ® øPø»ø¯  
  PØ£zvÚõ÷» Põn»õ® ÷\õvø¯ 
  PØ£zvÚõ÷» Põø»²[ Pmi÷h'' 
– v¸©¢vµ® 
The above verses of Thirumoolar bring out the importance and unique 
nature of Kalpa medicines in a nut shell. They are considered the elixirs of life. 
 According to Siddhars the human body is a replica representing the 
entire universe. The criteria by which the origin of an organism depends on 96 
thathuvas or constituent principles. To elevate the soul on its spiritual journey 
the siddhars formulated an applied alchemy, the Kaya kalpam. 
 The kaya kalpa – A preamble 
 Kaya – Body, mind and psyche 
 Kalpa – transmutation. 
 Kayakalpa is a transformative approach to health and consciousness to 
prevent diseases and to use chronic illness. Besides rejuvenating the body it 
also possess prophylactic action. According to Siddha Materia Medica kaya 
kalpa formulations  include herbs, minerals and the animal kingdom. 
 In general karpam is classified into two pothu karpam and sirapu 
karpam. 
The drug selected – Thaetran Karpam comes under Sirapu Karpam. 
According to Siddhars when taken as a Karpa medicine it treats diseases like 
Paandu, Magodharam, Soolai, Moolam, Perumbadu and many other diseases 
very efficienctly.  
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 TØöÓß  ÖøµUSÂÈU ÷Põ©Í÷© ! G¨÷£õx® 
 FØÓõ® ¤µª¯¬® Em¦sq® & BØÓÂ»õÀ 
 öÁmøh  APUPk¨¦® ÃÔ  Á¶Ø÷ÓØÓõ[ 
 öPõmøhuøÚ  }ö¯kzxU öPõÒ 
 
 ÷uØÓõ® Âøu¯x uõß w£Úzøu¨ ÷£õUS©ÚÀ 
 BØÖª¸ PsqU P¸©¸¢uõ® & TØÓõ 
 °¸zx[ Q¶a\õµzøu G[Sª»õ & ÷uõmk[ 
 S¸zxÁ ¬s hõUS[ SÔ 
     & APzv¯º SnÁõPh® 
 
CÀ»õ ©»P ªµsk ©°ßÓõ÷Úõ 
°À»õ ©»P ª¸US÷© & CÀ»õ©À 
ÁõøÇU PÛ²® Áøh² ªÊx¬s£õß 
ÁõøÇU  PÛ²ßøÁz uÁß. 
     & ÷u. ¯©P öÁs£õ 
 
 These verses of Thaerayar and Agathiar bring out  efficacy  of Thaetran 
in treating several diseases as a Karpa medicine. As quoted in ‘Agathiar 
Attavanai Vaagadam’ Thaetran Karpam can be used in the treatment of Paandu 
noi when administered along with ghee. 
According to WHO Paandu “(Anaemia) is the world's second leading 
cause of disability and thus one of the most serious global public health 
problems. It affects over half of pre-school children and pregnant women in 
developing countries and atleast 30-40% in industrialized nations. In poorer, 
malaria endemic countries it is one of the commonest preventable causes of 
death in children under 5 years and pregnant women. 
 Reducing the burden of the disease will make a major contribution to 
achieving several on millennium development  goals. Since the greatest burden 
of the disease falls on the most "hard to reach" individuals, any program that 
aims to reduce it will need to be accessible by these groups. Primary health 
care policies and programmes must be cornerstone of health care systems. 
Intervention which have been shown to impact on Paandu noi include 
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improving nutrition and iron status and treating helminth and malaria 
infections" 
 To tackle the varied aspects of Paandu (anaemia) wherein the main 
problem lies in malnutrition  Kalpa medicines of Siddha literature is the best 
option. Despite the availability of an array of treatment in other systems there’s 
still a heavy dependence on herbal medicines for the treatment of Paandu noi. 
 Present study was undertaken to evaluate the efficacy of the Thaetran in 
treating Paandu noi. 
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AIM 
 To evaluate the efficacy of Thaetran karpam in the management of 
Paandu. 
OBJECTIVES 
 To identify the crude drug and to study the pharmacongnostic features of 
the seed which include macroscopic and microscopic details of the part 
used as medicine. 
 To subject the drug to phytochemical and biochemical analysis. 
 To study the antimicrobial activity of the drug. 
 The study of pharmacological activity and acute toxicity of the drug. 
 To evaluate the efficacy of the drug clinically. 
 To analyse all the above study results to evaluate the efficacy of the 
drug. 
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REVIEW   OF  LITERATURE 
Gunapadam Aspect 
 
÷uØÓõß1 
Botanical Name  : Strychnos potatorum Linn11 
 
÷ÁÖ ö£¯º   : CÀ»®, PuP®,  ]À»®, ÷uÖ 
 
÷uzuõ[ öPõmøh¨ ÷£øµa ö\¨£U÷PÐ 
öuÎÁõÚ \uP©õ ö©zv}¯¢ 
uõ¢uõÚ u°»Áõ¶¨ ¤Ó \õuÚ©õ¢ 
uso²g ÷\øµ²¢uõß ÷ÁÓõUQ 
²zuõÚ ²h¼ÛØ ¬ÔPõÍõS 
¬¯ºQßÓ ÷{zvµ ÷µõPU QÛ¯õS® 
©õzuõÚ w£¢ v¸ènµ÷©P 
©¸Â¯ ÷uõº ÷uzvÝh  Úõ©©õ÷©.... 
– ÷£õPº |Psk 12007 
 
£¯ß£k®  EÖ¨¦ : £Ç®, Âøu 
 
_øÁ   : øP¨¦ 
 
ußø©  : öÁ¨£® 
 
¤¶Ä  : Põº¨¦ 
 
ö\´øP  : EhÀ ÷uØÔ  
Eµ©õUQ 
£]zwysi 
]Ö ÷PõøÇ¯PØÔ 
EÒÍÇ»õØÔ 
 
Sn® :  
 
CÀ»õ ©»P ªµsk ©°ßÓõ÷Úõ 
°À»õ ©»P ª¸US÷© & CÀ»õ©À 
ÁõøÇU PÛ²® Áøh² ªÊx¬s£õß 
ÁõøÇU  PÛ²ßøÁz uÁß. 
    & ÷u. ¯©P öÁs£õ 
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÷uØÓõß, ÷Áº, Âøu, £møh, Cø», PÛ Põ´ PØ£ ¬øÓ°ß£i FÖPõ´ 
xøÁ¯À, Si}º ¬u¼¯øÁPÍõP ö\´x uUP  £zv¯zxhß ÁÇ[QÚõÀ £Àø»,  `ø»Á¼, 
÷©PÄmhn®, £õsk, ö£¸Á°Ö, -»®, ö£¸®£õk, ÷\õøP, -ºaø\ Áõ², uÝºÁõ² 
¬u¼¯ ¤oPÒ }[S®. 
 
 TØöÓßÖøµUSÂÈU ÷Põ©Í÷© ! G¨÷£õx® 
 FØÓõ® ¤µª¯¬® Em¦sq® & BØÓÂ»õÀ 
 öÁmøh  APUPk¨¦® ÃÔ  Á¶Ø÷ÓØÓõ[ 
 öPõmøhuøÚ  }ö¯kzxU öPõÒ 
 
 ÷uØÓõ® Âøu¯x uõß w£Úzøu¨ ÷£õUS©ÚÀ 
 BØÖª¸ PsqU P¸©¸¢uõ® & TØÓõ 
 °¸zx[ Q¶a\õµzøu G[Sª»õ & ÷uõmk[ 
 S¸zxÁ ¬s hõUS[ SÔ 
     & APzv¯º SnÁõPh® 
 
 Âøu°ÚõÀ öÁÒøÍ öÁmøh, Em`k, ªS£], Á°ØÖUPk¨¦, ]Ö}º G¶a\À, ¦s 
BQ¯øÁ }[S®. ©¢u® EshõS®. Cx PsqUS {ß©¸¢uõS®. 
 
©¸zxÁ¨ £¯ß 
 
• 325  & 620 ª.Q. AÍÄ öPõÒÍ ^uUPÈa\À Eh¼À Eshõ® SzuÀ, Á¼ 
¬u¼¯øÁ ÷£õ® & EhØS Áßø© EshõS®. Bsø© ö£Ö®. 
• CuÝhß C¢x¨ø£ ÷\ºzxøµzxU Pso¼h, Ps ]ÁzuÀ }[S®. 
• Âøuø¯ ö£õizx £õ¼À P»¢x EÒÐUS öPõkUP, }µa_¸US öÁmøh 
¬u¼¯Ú w¸®. 
• Cuß ö£õiø¯ ÷uÛØ P»¢x PmiPÎß «x §]Áµ,PmiPÒ ^UQµ® £Êzx 
Eøh²® }¶Ø P»¢x vÚª¸÷ÁøÍ EmöPõsk Áµ  ©õº¦a\Î ÷PõøÇUPmk 
CÍQ öÁÎ¨£k®. 
• ]Ô¯ AÍÂÀ SÇ¢øuUSU öPõkzx Áµ»õ® Gß£øu ""÷uØÓõß 
öPõmøh°mk ÷uØÖ ø©¢uøµ'' GßÝ® ÷©Ø÷PõÍõ»Ô¯»õ®. 
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÷uØÓõß Âøu Si}º 
÷uØÓõß ÂøµPkUPõ¯ ö\¨£¶¯ ÁõÁõøµ  
÷¯ØÓ ÂÍõ® ¤]÷Úõ izuøÚ²[ & ÷PõØöÓõi¯õ´  
£[Põ ¯ÖPõØ £_Âß ÷£õ¶Ø£¸P¨ 
ö£õ[Q Á¸ }¶ÈÄ ÷£õ®. 
÷uõØÓõß Âøu, PkUPõ´ , BÁõøµ, ÂÍõ®¤]ß CøÁ {õßøP²® 
Jöµøh¯õP  Gkzx, £_Âß ÷©õ¶À P»¢x J¸ {õøÍUS BÖ ¬øÓ £¸Q Áµ }¶ÈÄ 
}[S®. 
÷uØÓõß öPõmøh ÷»Q¯® 
÷uØÓõß Âøu 170 Qµõ® v¶PkS , v¶£ø», ]ØÓµzøu, ^µP® ÁøPUS 
17 Qµõ® Gkzx¨ö£õi¯õUQ Azxhß \ºUPøµ 136 Qµõ® BÂß£õÀ 1400 ª.¼  
Pøµzx, £õS Põ´a] ÷©Ø£i ö£õiPøÍ²®  BÂß ö{´ J¸ £iø¯²® P»¢x, {ßÓõP 
Qsi RÌ CÓUQ øÁzxUöPõsk, ÷uß 700   ª.¼. ÂmkUQÍÔ  Gkzx, J¸ 
öPõmøh¨ £õUS AÍÄ Põø» ©õø» C¸ ÷ÁøÍ¯õP, {õP£Ø£zxhß C¸£x {õÒ 
EmöPõsk Áµ, CøÍ¨¦ ÷{õ´, C¸©À G¾®¦a_µ® ¬u¼¯Ú ÷£õ® EhØS Fmh® 
EshõS®.  Bsø© ö£¸S®. 
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÷uØÓõß ÷\¸® £õskÂØPõÚ  ©¸¢xPÒ   
uõx ¦èi ÷»Q¯®9 
{ßÚõ¶ ÷Áº 1 ÷\º,  uspº Âmhõß QÇ[S & 1 ÷\º, £møh }UQÚ ÂÀÁ 
^ÁÀ 3 ÷\º CøÁPøÍ ö{õÖUQ 8 £i á»zv¼mk Põ´a] 2 £i¯õUQ Azxhß 3 ÷\º 
PØÓõøÇa \õÖ, 3 ÷\º §\oUPõ´a \õÖ, Põ¨¤ öPõmøh°ß Påõ¯® ½ ÷\º, 
£_®£õÀ 5 ÷\º, £ßÜº & 1¼  ÷\º CøÁPøÍ ÷\ºzx Põ´a], PØPsk 3 ¾  ÷\º 
÷£õmk £õS ö\´x AvÀ  _US, ªÍS, ]ØÓµzøu, Pshzv¨¤¼, Qµõ®¦, H»®, 
K©®, ÷µõáõ ö©õmk , \¨áõ Âøu CøÁ £»® 2, v¨¤¼, ^ø©, A¬UQµõUQÇ[S, 
^µP®, ©À¼, }º¬ÒÎ Âøu, §øÚUPõ¼ Âøu, uõ©øµ Âøu, ¬¸[øPÂøu, 
AÀ¼Âøu, B»®Âøu Aµ\ Âøu, BÎ Âøu, ÷uØÓõßöPõmøh, |»¨£øÚUQÇ[S, 
P¸÷Á»®¤]ß, ¬¸[øP¤]ß, \õvUPõ´, \õu¨£zv¶, ÁõÀ ªÍS, P\P\õ ÁøPUS £»® & 
1 CøÁPøÍ `µozx ÁiPmiÚ yøÍ²®, Áõx ö©´£¸¨¦ &1  ÷\º S[S©¨§ & 1 ÁµõP 
öÚøh ÷\ºzx ø© ÷£õ»øµzx  CÁØÖhß, ö{´ & 2½ ÷\º ÷uß & 1 ÷\º CøÁPÐ® 
÷£õmkU Qsi ÷»Q¯ £uzvÀ CÓUQ vÚ® Põø» ©õø» ¦ßøÚUPõ´ AÍÂÀ u[P 
÷µUS AÀ»x u[P £Ø£®, Aøµ SßÔ©o Gøh øÁzx \õ¨¤mk Áµ Cµzu 
Â¸zv²®,uõx ¦èi²® EshõQ Â¢xUPmk® ÷£õPªS®, £zv¯ªÀø». 
÷uØÓõß ÷\¸® £õskÂØPõÚ ¤Ó ©¸¢xPÒ 
1. ©PõÂÀÁõv CÍP®10 
2. ^µPõv CÍP®10 
÷uØÓõß ÷\¸® ¤Ó ©¸¢xPÒ 
1. ÷uØÓõß öPõmøh ÷»Q¯®10 
2. ÷uØÓõß Q¸u®9 
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Strychnos potatorum  (Botanical aspect)11,12,48 
FAMILY : Loganiaceae 
VERNACULAR NAMES: 
 Eng   : Clearning nut tree, clearing nut  
 Hindi  : Nirmali, Nelmal, Chilli, Kavi,  
Marathi :  Nirmal 
 Punjabi : Nirmal 
 Kannada : Cilu : Cilledabija, Katakam 
 Malayalam : Tettamaram, tettamparai 
 Sanskrit : Katakah, Ambuprasadah 
 Tamil  : Tettamaram, Tettankotai 
 Telugu : Kataka nu, Indupacettu 
 Bengali : Nirmal 
 Gujarati : Nirmal 
Bentham and Hooker Classification31 
Kingdom    - Plant kingdom 
    Division    - Phanerogams 
        Class    - Dicotyledons 
Subclass   - Gamopetalae 
    Series   - Bicarpellatae 
        Order   - Gentianales 
  Family   - Loganiaceae 
      Genus  - Strychnos 
           Species - potatorum  
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Habit:   
Deciduous forests of West Bengal, Central and South India upto 1200m. 
Description: 
 A medium sized, deciduous, glabrous tree about 12 m in  height with 
cracked and scaly black bark and irregularly fluted trunk. 
Leaves : 
Simple, opposite, elliptic, acute, upto 15 cm long and 6.25 cm broad, 
transverse nerves about 4 pairs joining the second pair of ribs to the midrib, 
glabrous, shining. 
Flowers: 
 White, fragrant, axillary cymes 
Fruits: 
 Ovoid or globose, glabrous berries, black when ripe 
Parts used: 
 Seeds 
ACTION AND THERPEUTIC USES 
The seeds possess 
- Tonic 
- stomachic 
- Demulcent and emetic properties 
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- Used in the treatment of diarrohea, diabetes, gonorrhoea etc. 
- They are of primary importance in the treatment of eye diseases, 
particularly conjunctivitis. 
- The leave are used as poultice for maggot – infested ulcers. 
- Rendered bark is useful in cholera. 
CHEMICAL CONSTITUENTS13 
 An alkaloid – diaboline, sterols – ß silosterol, stigmasterol, oleonalic 
acid,  a saponin containing oleanolic acid, galactose and mannose are isolated 
from seeds. Galactose and mannose are also isolated as free sugar from the 
seed. Indole alkaloids galacto mannan and  galactan are found in the ratio 1:1.7. 
Phytochemical studies of strychnos potatorum  
PHYSIO CHEMICAL PROPERTIES 
Analysis of finely powdered seeds gave: 
 Foreign matter   Not more than 2% 
Total ash   Not more than 2% 
Acid insoluble ash   Not more than 0.5% 
Alcohol    soluble  extractive – Not less than 1% 
Water    soluble extractive – Not less than 5% 
Moisture  8.26% 
Nitrogen  1.33% 
Sucrose  1 – 2% 
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Quantitative estimation of phytochemicals in the seeds 
 Metabolites Results in % 
1 Alkaloids 1.3 
2 Flavonoids 0.021 
3 Phenols 0.059 
4 Tannins 18.00 
5 Saponins 4.741 
 
Alkaloids are the lead molecules of therapeutic importance of Thaetran 
which have been proved to be having properties such as hypotensive activity, 
anti convulsant activity, anti protozoal, antimicrobial and anti malarial 
activities. 
The data generated from the experimental studies have provided the 
chemical basis for the wide use of Thaetran for various ailments. 
Studies of Strychnos potatorum Linn seeds44 
 Hepatoprotective and antioxidant actions of Strychnos potatorum 
Linn. Seeds in CC14 – includes acute hepatic injury in experimental rats. 
Hepatic injury was achieved by injecting 3 ml/kg of CCl4 in equal proportion 
with olive oil. Both SPP (seed powder) and SPE (aqueous extract) at the doses 
100 and 200 mg/kg p.o offered significant (P < 0.001) hepatoprotective action 
by reducing the serum marker enzymes likes SGOT (serum glutamate  oxalo 
acetate transaminase) and SGPT (Serum glutamate pyruvate transminase. They 
also reduced levels of serum bilirubin. Reduced enzymic and non enzymic 
antioxidant levels and elevated lipid peroxide levels were restored to normal  
by administration of SPP and SPE. Histopathological studies further confirmed 
the hepatoprotective activity of SPP and SPE when compared with the CCl4 
treated control groups. The results obtained were compared with Silymarin (50 
mg /kg p.0) the standard drug.  In conclusion the SPE (200 mg/kg p.o) showed 
significant hepatoprotective activity similar to that of the standard drug. 
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 Studies on the antiulcerogenic potential of S.potatorum Linn. seeds47 
on aspirin plus pyloric ligation (Aspirin + pL) at two doses 100 and 200 mg/kg 
p.o prevented ulcer formation by decreasing acid secretory activity and 
increasing mucin activity in rats. The anti-ulcerogenic potential was further 
confirmed by histopathological studies of stomach mucosa. Compared with Std 
Ranitidine. The mucoprotective action of SPP and SPE may be due to the 
presence of polysaccharides in the seeds. 
Studies on anti diarroheal activity of Strychnos potatorum47 
 Methanol extract of seeds (MESP) – 100, 200 and 400 kg p.o) 
significantly inhibited the frequency of defaecation and reduced the wetness of 
faecal droppings in castor oil induced diarroheal. Also decreased the propulsion 
of charcoal meal from the GI tract.  
Studies on diuretic activity  
Methanol extract of the seeds (600 mg/kg)47 exhibited significant 
diuretic activity. Excretion of  cations (Na and K ions) and chloride ions also 
were significant compared with standard Furosemide.  
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MATERIALS AND METHODS 
METHODOLOGY FOR PHARMACOGNOSY STUDY14 
 
 Mature seeds Strychnos potatorum  Linn. (Fam. Loganiaceal) 
were purchased from chennai drug market and identified by Dr.Sasikala 
Ethirajulu, Botanist, Central Research Institute for Siddha, Arumbakkam, 
Chennai – 106. 
The seeds of Strychnos potatorum were fixed in formalin – acetic – acid 
– alcohol and later stored in 70% ethanol. They were dehydrated through 
tertiary butyl alcohol series and embedded in paraffin work in the usual way. 
Microtome sections  10 to 16 µm thick were stained with safranin-fast green 
combination. All permanent slides after staining  were dehydrated by 
employing graded series of ethyl alcohol and xylol and mounted in Canada 
balsam (Johansen, 1940). Embroys were dissected out after soaking the seeds 
for 24 hrs. in distilled water. 
 Photomicrographs were made at different magnifications depending 
upon the anatomical details to be brought out. Photomicrography was done on 
Nikon Eclipse E200 microscopic unit. 
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RESULT 
Macroscopic 
 Seed upto 8 mm dia., circular, bluntly lenticular, shiny with short, 
appressed silky hairs, cream-white in colour with a slightly prominent ridge 
round the border, no bitterness. 
Microscopic 
 Shows testa, consisting of 2 or 3 layers, thick walled, elongated, 
lignified sclerenchymatous cells covered with numerous, cylindrical, 
unicellular lignified, trichomes having basal portion ramified. Outer endosperm 
composed of 3 to 8 layers of thick walled, elongated palisade – like cells 
arranged in rows, an inner endosperm composed of thin-walled, oval to 
polygonal, parenchymatous cells having numerous  small aleurone grains and 
oil globules. 
Powder 
 Creamish – yellow, shows fragments of testa, trichomes, endosperm 
cells and oil globules. 
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PREPARATION OF CHOORNAM 
THAETRAN KARPAM (Strychnos potatorum) 
COLLECTION OF THE DRUG 
 The drug selected Thaetran Karpam (Thaetran Kottai Choornam) has 
been mentioned as good remedy for Paandu noi in Agathiar Attavanai 
Vagadam p-30. 
 The seeds were obtained from an indigenous drug store and identified by 
a botanist. 
PREPARATION AND STORAGE  
Purification 
 The seeds were washed in fresh water, cleaned thoroughly and were 
allowed to dry in shade.  
 The seeds were then further purified by soaking in cow’s milk for about 
25 mins and then washed and dried in shade. They were then boiled in the juice 
of Amaranthus tricolor, washed and were allowed to dry in shade. 
Preparation of choornam 
 The dried seeds were fried and made into fine powder and sieved 
through a white cloth (Vasthira kaayam). Then it was purified by steam – 
cooking in milk (Pittavial method). The same was later powdered and sieved 
again and preserved. 
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Storage of Choornam 
 The choornam was stored in a clean airtight container.  
Administration of the drug 
 Route of administration  : Enteral 
 Dosage    : 1 gm twice a day 
 Vehicle    : 5 ml of Ghee 
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ANTI MICROBIAL STUDY 
 
Method 
The anti-microbial activities of different extracts of THAETRAN 
KARPAM were studied by  Disc diffusion method against the following 
organisms. 
1. Streptococcus mutans 
2. Staphylococcus aureus 
3. Escherichia Coli 
4. Klebsiella pneumoniae 
5. Pseudomonas aeruginosa 
Extracts of  Thaetran Karpam were used in the concentration of 100, 50 
and 25 µl using their respective solvents. Ciprofloxacin, (5 mcg/disc) used as 
standard. The disc diffusion method was employed for the screening of anti-
bacterial activity. 
Disc diffusion method 
 A suspension of organism was added to sterile soya bean casein digest 
agar media at 45°C, the mixture was transferred to sterile petridishes and were 
allowed to solidify. Sterile discs, 5mm in diameter, dipped in solutions of 
different extracts, standard and a blank was placed on the surface of agar 
plates. The plates were left standing for one hour at room  temperature as a 
period of pre incubation diffusion to minimize the effects of  variation  in time 
between the applications of the different solutions. Then the plates were 
incubated at 37°C  for 18 hours and observed for anti-bacterial activity. The 
diameter of zones of inhibition were observed and measured. The average area 
of zones of inhibition were calculated and compared with that of standard's. 
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RESULTS FOR ANTIMICROBIAL STUDY 
Zone of inhibition in mm 
Organism 
Standard 
drug 
ciprofloxacin 
50 mcg/disc 
Test drug (Thaetran Karpam µl/disc) 
Zone of inhibition in mm 
25 µl 50 µl 100 µl 
Strep. mutans 30 14 17 20 
Staph. aureus 31 16 19 22 
E.coli 30 15 18 20 
K.pneumoniae 30 18 21 24 
Ps aeruginosa 30 14 20 23 
 
Standard used for bacteria 
 Ciproflaxacin Hcl, 5 mcg / disc 
Sample concentration 
 1.5 gm / 150 ml of solvent. 25 µl, 50 µ & 100 µl/ disc  
14 mm -  Low sensitivity,  15 mm – Moderate above 16 mm – Highly 
sensitive.  
Inference 
Thaetra Karpam was found to be highly sensitive to strep. mutans, stap. 
aureus, E.coli, K.pneumoniae and Ps aeruginosa. 
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IDENTIFICATION OF THE CONSTITUENTS OF THAETRAN 
KARPAM BY PHYTOCHEMICAL TESTS 
The drug powder and various extracts of Thaetran Karpam were  
subjected to chemical tests for identification of its active constituents. 
Test for alkaloids 
 A small portion of the  solvent, free chloroform, alcoholic and aqueous 
extracts were treated separately with few drops of dilute Hcl and filtered. The 
filtrate may be tested carefully with alkaloidal reagents such as, 
 a. Mayer's reagent  - Yellow precipitate 
 b. Dragendroff's reagent - Orange brown precipitate 
 c. Wagers' reagent  - Reddish brown precipitate 
Test for Carbohydrates 
 Molisch's test 
 Filterate was treated with 2-3 days of 1% alcoholic alpha-napthol 
solution and 2 ml of concentrated H2SO4 was added along the sides of the test 
tube. Appearance  of brown ring at the junction of 2 liquids show the presence 
of carbohydrates. 
Test for Glycosides 
 Another portion of  Thaetran Karpam was hydrolysed with Hcl for few 
hours on a water bath and the hydrolysate was subjected to legal's Berntragers' 
test to detect the  presence of glycosides. 
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a. Legal's test 
 To the  hydrosylate, 1 ml of pyridine and few drops of sodium nitro 
prusside solution were added and then it was made alkaline with sodium 
hydroxide solution. Appearance of pink to red colour shows the presence of 
glycosides and aglycones. 
Lieberman burchard test 
 1 gm of the extract of Thaetran Karpam was dissolved in few drops of 
dry  acetic acid. 3 ml of acetic anhydride was added followed by few drops of 
concentrated sulphuric acid. Appearance of bluish green colour shows the 
presence of phytosterol. 
Test for saponins 
 The extracts of Thaetran Karpam was diluted with 20 ml of distilled 
water and it was agitated on a graduated cylinder  for 15 minutes. The 
formation of 1 cm layer of foam shows the presence of saponins. 
Test for Tannins and Phenolic compounds 
 Small quantities of various extracts were taken separately in water and 
tested  for the presence  of  phenolic compounds  and tannis by adding  2 ml of 
10% lead acetate and 2 drops of FeCl3 solution. Presence of tanin and phenolic 
compounds is denoted by white precipitate and blue black colour respectively. 
Test for proteins and free amino acids 
 Small quantities of various extracts of Thaetran Karpam were dissolved 
in a few ml of water and treated with Hindryin reagent. Appearance of purple 
color shows the presence of proteins and free amino acids. 
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Test for flavanoids 
 With aqueous sodium hydroxide solution the extract gives blue to violet 
colour if anthocyanins are present, yellow colour if flavones are present, 
yellow, to orange if flavanones are present. 
Test for Tannic Acid 
 The extract is treated with ammonium molybdate and conc. HNO3, 
formation of blue black precipitate indicates the presence of tannic acid. 
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METHODOLOGY  FOR BIO-CHEMICAL ANALYSIS 
Preparation of extract 
 5 gm of Thaetran Karpam was weighted accurately and placed in a 250 
ml clean beaker and added with 50 ml of distilled water. Then it was boiled 
well for about 10 mins. Then it was cooled and filtered in a 100 ml volumetric 
flask and made upto 100 ml with distilled water. 
Test for Calcium 
 2 ml of extract was taken in a clean test tube. To this 2ml of 4% 
ammonium hydroxide solution was added. Presence of calcium is denoted by 
formation of a white precipitate. 
Test for Iron (ferric) 
 The extract was treated with glacial acetic acid and potassium 
ferrocyanide. Presence of  ferric iron is denoted by a blue colour. 
Test for Iron (Ferrous) 
 The  extract was treated with conc. HNO3 and ammonium thiocyanate. 
(Presence of Ferrous iron is denoted by formation of a blood red colour) dilute 
ferric chloride solution (5%). The  formation of violet colour shows the 
presence. 
Test for sulphate 
 2 ml of the extract was added to 5% barium chloride solution. Presence 
of sulphate is denoted by formation of a white precipitate. 
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Test for  Chloride 
The extract was treated with silver nitrate solution. The presence of 
chloride is denoted by formation of a white precipitate. 
Test for  Carbonate 
The extract was treated with concentrated Hcl. If carbonate  is present, it 
is denoted by effervescence. 
Test for  Phosphate 
Te extract was treated  with ammonium molydate and conc. HNO3. If 
phosphate is present, it is denoted by the formation of a yellow precipitate. 
Test for unsaturation 
 1 ml of Potassium permangnate solution is  added to the extract. The 
presence  of  unsaturation is denoted by  decolourisation. 
 25
RESULTS FOR ACID, BASIC RADICALS AND PHYTOCHEMICAL 
SCREENING OF THAETRAN KARPAM 
The following constituents were present. 
Acid radicals 
 Sulphate 
Basic radicals 
 Calcium 
 Iron (ferrous) 
Phytochemicals 
 Tannic acid 
 Sugar (trace)  
 Alkaloids 
 Steroids 
 Proteins  
 Tannins 
 Phenols 
 Flavonoids 
 Saponins 
 Aminoacid 
 Glycosides 
Miscellaneous 
 Unsaturation present. 
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QUANTITATIVE ANALYSIS 
 
 
 
Equipment used : Absorption Spectrometer (AAS) 
Make : Varian, Australia 
 
S.No. Test Parameter Results 
1 Iron as Fe 373.0 mg /kg 
 
Inference 
 
 The sample had 373.0 mg/kg of iron. 
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METHODOLOGY FOR THIN LAYER 
CHROMATOGRAPHY 
 2g of the sample was soaked in 20 ml of rectified spirit (90%) for 18 hrs 
and boiled for 10 mins and filtered. The filtrate was concentrated and made 
upto 5 ml. 25µl of  alcoholic extract was applied on Merck Aluminium plate 
pre-coated with Silica gel 60F254 of 0.2 mm thickness along with the 
ingredients using Linomat IV applicator. The plate was developed in Toluene; 
ethyl acetate 5:1..5 v/v. The plate was visualized UV 254 and 366 nm. The 
plate was then dipped in Vanillin – Sulphuric acid and heated in air oven at 
105°C till the spots appeared. 
TLC TEST RESULTS 
Sl.No. 
UV 254 nm UV 366 nm With spray reagent 
Colour Rf Colour Rf Colour Rf 
1 - - Blue 0.11 Grey 0.11 
2 - - - - Grey 0.22 
3 Grey 0.28 Dark 
Blue 
0.28 Grey 0.28 
4 Grey 0.42 Blue 0.42 Grey 0.42 
5 Grey 0.50 Blue 0.50 Grey 0.50 
6 - - Blue 0.56 - - 
7 - - Blue 0.69 Grey 0.67 
8 - - -  Grey 0.75 
9 - - -  Grey 0.83 
 
INFERENCE 
 The Rf values for Strychnos potatorum were found to be 0.28, 0.42, 0.50 
with UV 254 nm, 0.11, 0.28, 0.42, 0.50, 0.56, 0.69 with UV 366 nm and 0.11, 
0.22, 0.28, 0.42, 0.50, 0.67, 0.75, 0.83 with spray reagent. 
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PHARMACOLOGICAL STUDIES 
Preparation of drug for dosing 
 All drugs used for the study was suspended each time with 1% (w/v) 
solution of sodium carboxy methyl cellulose before administration. 
Drugs and chemicals 
 Histamine hydrochloride and fine chemicals used in these experiments 
were obtained from Sigma Chemicals company, U.S.A. Other analytical grade 
chemicals were obtained from S.d. Fine Chemicals Ltd., Mumbai. 
Experimental animals  
 Colony inbred animals strains of wistar rats of either sex weighing 200 - 
250 g were used for the pharmacological studies and Swiss albino mice 
weighing 20 – 25g were used for toxicological studies. The animals were kept 
under standard conditions 12:12 (day/night cycles) at 220C room temperature, 
in polypropylene cages. The animals were fed on standard pelleted diet 
(Hindustan Lever Pvt Ltd., Bangalore) and tap water ad libitum. The animals 
were housed for one week in polypropylene cages prior to the experiments to 
acclimatize to laboratory conditions. The experimental protocol was approved 
by the Institutional Animal Ethical Committee (IAEC). 
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Acute oral toxicity study     
Acute oral toxicity was conducted as per the OECD guidelines 
(Organization of Economic Cooperation and Development) 423 (Acute Toxic 
Class Method). The acute toxic class method is a stepwise procedure with 3 
animals of a single sex per step. Depending on the mortality and /or moribund 
status of the animals, on the average 2-4 steps may be necessary to allow 
judgment on the acute toxicity of the test substance. This procedure results in 
the use of a minimal number of animals while allowing for acceptable data 
based scientific conclusion. 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) 
and the results allow a substance to be ranked and classified according to the 
Globally Harmonized System (GHS) for the classification of chemicals which 
cause acute toxicity 
Swiss albino mice of the same weighing 20-25 g were fasted overnight, 
but allowed water ad libitum. Since the formulation Thaetran Karpam is 
relatively non toxic in clinical practice the highest dose of 2000 mg/kg/p.o (as 
per OECD guidelines “Unclassified”) was used in the acute toxicity study.   
The animals were observed closely for behavioural toxicity, if any by 
using FOB (Functional observation battery). 
Results for Acute oral toxicity study 
Thaetran karpam at the dose of 2000mg/kg/po did not exhibit any 
mortality in rats. As per OECD 423 guidelines the dose is said to be 
“Unclassified” under the toxicity scale. Hence further study with higher doses 
was not executed.  
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Studies on  haematinic activity 
 Adult wistar rats of either sex weighing 200 – 250 g were taken. 12 – 16 
hrs before the experiment began the rats were fasted but water was made 
available – ad libitum. The initial blood parameters were noted. The animals 
were randomly divided into 3 groups of 6 animals each.  
 Group 1 served as the control group and was orally given 10 ml/kg body 
wt of distilled water. Group 2 served as the standard group and was orally 
given (fefol capsules). Group 3 served as the and the test group was 
administered the test drug Thaetran Karpam at the dose of 500 mg/kg body wt 
for 15 days and results were tabulated. 
Effect of  Thaetran karpam  on Haematological parameters after 15 days  
repeated oral dosing (500 mg/kg) 
Groups Hb (gm/100ml) 
RBC 
(millions/cu.mm) 
WBC  
(Cells/ comm. ) 
Control 8.51 ± 2.049 2.898 ± 0.609 5438.33 ± 3.78 ns 
Thaetran 
karpam 
10.66 ± 0.930*** 3.532 ± 0.303 ** 5132.00 ± 3.01 ns 
Std fefol 13.5 ± 0.862 6.562 ± 0.962 8537.00 ± 3.05 
 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
***P<0.001 as compared with that of control,  
**P<0.003 as compared with that of control,      
Ns – non significant when compared to control groups . 
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Groups 
PCV 
% 
MCV MCH 
Control 28.25 ± 1.101 89.8 ± 0.670 30.33 ± 0.117 
 
Thaetran 
karpam 
35.0 ± 0.836ns 
 
90.67 ± 0.497ns 30.43 ± 0.526 ns 
 
Std. fefol 51.3 ± 3.23 110.95 ± 0.927 37.52 ± 2.72 
 
 
n=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
ns – non significant when compared to control groups . 
 
 
Inference 
 
In the present study 15 days continuous administration of the TK at the 
dose of 500 mg/kg/p.o showed significant increase in Hb% of animals with a 
concurrent increase in RBC count. However there wasnt any significant rise in 
PCV, MCV, MCH levels. 
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CLINICAL ASSESSMENT  
 
About the disease 
£õsk5 
 
÷ÁÖö£¯º: öÁÐ¨¦ ÷{õ´, öÁsø© ÷{õ´ 
C¯À¦:  C¯ØøP |Ó® ©õÔ, EhÀ öÁÐzx Psøn²® {PU Psøn²® }UQ £õºUQß 
S¸v°ßÔ öÁÐzv¸US®. 
÷{õ´ ÷uõßÖ® ÁÈ 
 S¸v°ß Áßø©ø¯U SøÓUP Ti¯ E¨¦, ¦Î¨£õÚ ö£õ¸ÒPøÍ ªSv¯õPU 
öPõÒÁuõ¾®, _µ®, ÷£v, Áõ¢v RÀ Áõ² ¬u¼¯ ÷{õ´PÐUSm£kÁuõ¾®, 
S¸vø¯ AÍÄ Ph¢x  öÁÎ¯õUS®. ö£¸®£õk, S¸v¯ÇÀ ÷{õ´, S¸v PÈa\À -øÍ ÷{õ´, 
S¸v Áõ¢v ¬u¼¯øÁ HØ£ku»õ¾® C¢÷{õ´ EshõS®. AßÔ²® 
{a_zußø©²øh¯ ©¸¢xPøÍ  {õÍÍÄUS ªg] Es£uõ¾®, Ehø»  CøÍUPa ö\´²® 
Á°ØÖ¨¦Ê ÷{õ´, CøÍ¨¦ ÷{õ´, |nUPÈa\À ¬u¼¯øÁPÍõ¾®, S¸v¨ ö£¸UøPU 
öPkUPUTi¯ DµÀ ÷{õ´PÍõ¾®, ¦øP°ø», öÁØÔø»  £õUS, ©s, \õ®£À, v¸}Ö, 
PØ§µ® ¬u¼¯øÁPøÍ AiUPi EmöPõÒÁuõ¾® C¢÷{õ´ Á¸®. 
SÔSn[PÒ 
 EnÄ ¬u¼¯  ÷ÁÖ£õkPÍõÀ, wUSØÓ ªS¢x S¸v°ß |Ózøu²® Gøhø¯²® 
öPkzx, EhØS ÷Ási¯ Fmhzøu²® öPõhõ©À 
1. Ehø» öÁÐUPa ö\´²® 
2. ¤ß¦ ]Ôx  öuõø»Ä  {hUQÝ® PõÀ K´{x ÷£õuÀ, ö£¸ -a_ Áõ[PÀ 
3. EnÂÀ Â¸¨£ªßø© 
4. Áõ´US©mhÀ 
5. Ps C¸ÍÀ 
6. AiUPi ©¯UP©õuÀ 
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7. ©õº¦ xizuÀ 
8. EhÀ CøÍzuÀ 
BQ¯ SÔPøÍ²® Põmk®. 
÷{õ´ Gs 
 SØÓzuõÀ Á¸ÁÚ  {õßS®,  {g\õÀ Á¸ÁÚ JßÖ® Ti I¢uõS®. 
1. ÁÎ¨£õsk  2. ¤zu¨£õsk  3. P£¨£õsk  4. ¬USØÓ¨£õsk  5. Âh¨£õsk  
GÚ I¢öuÚ ÁSzxÒÍÚº. CßÝ® ©sqß öÁÐ¨¦ ÷{õ´ JßÖÒÍx GßÖ® ]»º TÖÁº. 
 
C¢÷{õ°øÚ  }»¨£õsk, A»\¨ £õsk,  A¼¬P¨£õsk  GÚ -ÁøP¯õP 
ÁÇ[SÁµõ°Ý® CøÁ öÁÐ¨¦ ÷{õ°À Põq® SÔ Sn[PøÍ÷¯ ö£Ö©õu¼ß 
CÁØøÓz uÛzx  TÓ ÷ÁskÁvÀø». 
 
 
 
 
 
 
 
Selection of patients 
 The clinical study of Paandu Noi was carried out in out patient 
department of Arignar Anna Govt. Hospital of Indian Medicine and 
Homeopathy, Arumbakkam, Chennai. 
 34
 Cases from both sexes of varying age groups were selected. All the 
cases were carefully examined before treatment for correct diagnosis and ruled 
out any other co-existing systemic illness. 
Criteria for selection 
 Age  : All age groups 
 Sex : Both gender 
I. Inclusion criteria 
 1. Pallor of skin and nail beds 
2. Loss of appetite 
3. Fatigue 
4. Patients having haemoglobin level 7 – 9 mg/dL 
II. Exclusion criteria 
1. Haemorrhoids 
2. Haematuria 
3. Haemoptysis 
4. Repeated epistaxis 
a. Pregnant women 
b. Lactating mothers 
iii. Withdrawal criteria 
1. Irregular treatment 
2. Irregular visit 
Study design 
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 Open clinical trial 
Treatment schedule 
 Dosage : Thaetran Karpam – 1 g 
 Vehicle : 3 ml of Ghee / twice a day after food 
 Duration : 48 days 
Investigation parameters 
 The presence of anaemia was confirmed in all patients by means of 
blood picture 
 TC 
 DC 
 ESR 
 Hb 
Urine analysis for 
 Albumin 
 Sugar 
 Deposits 
 Stools examination for 
 Ova 
 Cyst 
 Occult blood 
 Occult blood ruled out for any systemic illness. Diagnosis was done on 
the basis of Siddha principles such as Envagai Thervugal and mukkutra 
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verupadu, 40 patients who were moderately anaemic were treated as out 
patients. They were adviced to attend the OP once in a week for follow up and 
general observation. 
Medical advice and Diet 
They were advised to take food that was easily digestible and readily 
absorbed. 
Observation and results of clinical study 
 The clinical study was subjected to 40 selected cases. The following 
parameters were observed during the course of treatment. 
 Age 
 Sex 
 Socio – economic status 
 Diet and Habit 
 Occupational status 
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Age Distribution 
Sl.No. Age in Years No.of Patients Percentage % 
1. 11 – 20 9 22 
2. 21 – 30 10 25 
3. 31 – 40 7 17 
4. 41 – 50 5 13 
5. 51 – 60 4 10 
6. 61 – 70 5 13 
 
 
Inference 
 Among 40 patients, 10% of the patients belonged to the age group of 51 
– 60, 13% of the patients belonged to the age group of  41 – 50 another 13% of 
the patients belonged to the age group of   61 – 70, 22% of the patients 
belonged to the age group of   21 – 30, 25% of the patients belonged to the age 
group of   11 – 20. 
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Sex Distribution 
Sl. 
No. Sex No.of Patients 
Percentage 
% 
1. Male 8 20 
2. Female 32 80 
 
 
 
Inference 
 80% of the patients were women and children and 20% were men. Most 
of the men were older in the age group of 60 – 70. 
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Habit wise distribution 
Sl.No. Habit and Diets No. of Patients Percentage % 
1. Vegetarian 12 30 
2. Mixed diet 20 50 
3. Smoking 5 13 
4. Alcohol 3 7 
 
 
Inference 
 This table shows that food and habit do not show any influence in case 
of anaemia. Among 40%, 50% had mixed diet, 30% had vegetarian food, 13% 
were smokers and 3% were alcoholics. 
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Socio economic status 
Sl.No. Socio economic status No.of Patients Percentage % 
1. Poor 28 70 
2. Middle class 7 17 
3. Rich 5 13 
 
 
 
Inference 
 Among 40 patients, 70% were poor, 17% belonged to the middle class 
and 13% were rich.  
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Occupation wise distribution 
Sl.No. Occupation No.of Patients Percentage % 
1. Homemakers 20 50 
2. Student 10 25 
3. Labourer 6 15 
4. Miscellaneous 4 10 
 
 
Inference 
 Occupation did not seem to have any influence in anaemia. Since the 
majority were women and children they were mostly home makers, and school 
or college students. 
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SYMPTOM WISE DISTRIBUTION 
Sl.No. Symptoms Before treatment
After 
treatment Improvement 
Percentage 
% 
1. Pallor of skin 
and nail beds 
32 9 23 72 
2. Loss of 
appetite 
34 5 29 85 
3. Fatigue 37 9 28 76 
 
 
Inference 
 Patients with the parameters of pallor of skin and conjunctiva, loss of  
appetite and fatigue were taken.  Among 32 patients with pallor 23 showed 
improvement, among 34 patients with of appetite 29 developed good appetite 
and among 37 patients with fatigue 28 showed good improvement. 
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Gradation of result 
Sl.No. Grade No.of Patients Percentage % 
1. Good 29 73 
2. Moderate 6 15 
3. Mild 5 12 
 
 
Inference 
 Among the 40 cases, 73% cases showed good results, 15% of cases 
showed moderate results and 12% cases showed mild results. 
 Development of good appetite and reduction of pallor, fatigue within 3 
weeks was considered as good improvement. 
 Improvement in 2 or more symptoms within 4 – 5 weeks was considered 
moderate. Improvement in less than 2 symptoms after 6 weeks was considered 
mild.  
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Haemoglobin in mg 
Sl. 
No. 
Name Age/Sex OP 
No. 
Date BT AT d 
Difference 
d2 
1. Sargunam 39/F 9876 19.10.07 8 11 3 9 
2. Yasodha 59/F 2439 29.10.07 8.5 11 2.5 6.25 
3. Kamini 18/F 2989 31.10.07 8.5 9 0.5 0.25 
4. Naveena 19/F 3597 27.11.07 7 10 3 9 
5. Anuradha 19/F 6133 12.11.07 9 9 0 0 
6. Sekar 60/M 4423 5.11.07 7.5 9 1.5 2.25 
7. Thangam 22/F 7665 16.11.07 8 13 5 25 
8. Subbulakshmi 55/F 7663 16.11.07 8 11 3 9 
9. Leela 23/F 8.47 17.11.07 8.5 9.5 1 1 
10. Ramesh 50/M 8267 17.11.07 6.5 8 1.5 2.25 
11. Kamakshi 25/F 8269 17.11.07 7.5 9.5 2 4 
12. Jaya 23/F 9104 20.11.07 9 10.5 1.5 2.25 
13. Agalya 15/F 956 26.11.07 7.5 9 1.5 2.25 
14. Sivamani 30/M 3190 1.12.07 6.5 9.5 3 9 
15. Uma 17/F 1973 28.11.07 7.5 11 3.5 12.25 
16. Kasthuri 45/F 3730 3.12.07 7 8.5 1.22 2.25 
17. Manju 12/F 3964 4.12.07 9 9.5 0.5 0.25 
18. Raguraj 64/M 9126 18.12.07 9 9 0 0 
19. Loganathan 85/M 9515 20.12.07 8.5 10 1.5 2.25 
20. Puspha 38/F 166 22.12.07 9 10.5 1.5 2.25 
21. Janani 15/F 1917 27.12.07 8.5 9 0.5 0.25 
22. Jothi 36/F 7098 11.1.08 8.5 10 1.5 2.25 
23. Dhanam 43/F 87.2 18.1.08 9 10 1 1 
24. Shanmugam 70/F 9889 22.1.08 6.5 9.5 3 9 
25. Bakianathan 65/M 9965 22.1.08 7 10 3 9 
26. Dhesamma 35/F 353 23.1.08 8.5 10.5 2 4 
27. Gayathri 19/F 771 24.1.08 8.5 9.5 1 1 
28. Banurega 36/F 796 24.1.08 9 11 2 4 
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Sl. 
No. 
Name Age/Sex OP 
No. 
Date BT AT d 
Difference 
d2 
29. Sellammal 55/F 773 24.1.08 9 10 1 1 
30. Kamalammal 60/F 1646 27.1.08 9.5 10 0.5 0.25 
31. Meenakshi 65/F 2668 29.1.08 8.5 10 1.5 2.25 
32. Suharbanu 28/F 45 30.1.08 10 10 0 0 
33. Dhayalan 35/F 3432 31.1.08 8.5 11 2.5 6.25 
34. Sasikala 65/f 545 31.1.08 9 9.5 0.5 0.25 
35. Kasiamma 65/F 3758 1.2.08 6.5 9 2.5 6.25 
36. Bhavani 35/M 8975 18.2.08 7 10 3 9 
37. Saraswathi 40/F 6728 6.3.08 10.5 14 3.5 12.25 
38. Latha 42/F 6003 4.3.08 8.5 9 0.5 0.25 
39. Srinidhi 28/F 6776 6.3.08 7.5 8 0.5 0.25 
40. Priya 18/F 3603 27.2.08 9 11.9 2.5 6.25 
 Total    329 399 70 175.5 
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Methodology for statistical analysis 
 The paired ‘t’ test is used for the analysis of paired data. The observed 
difference in each pair is calculated. The ‘t’ is determined by the following 
formula. 
n
s
dt
2
=  
 where  d is the mean of the differences is each pair. S is the standard 
deviation of the observed differences and n is the number of matched pairs. The 
number of degrees of freedom is  (n -1).  
 
75.1
40
20 ==d  
0766.0
1
2
2
2 =−
Σ−Σ
=
h
n
dd
s  
505.9
40
0766.0
75.1
/2
===
ns
dt  
 For t = 9.505 at 39 degrees of freedom P < 0.001. Therefore Theatran 
karpam has brought about a statistically highly significant increase in Hb 
content. 
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Statistical analysis of subjective parameters observed before and after 
treatment 
S.No. Parameter 
Percentage 
Statistical 
test 
criterion 
Probability 
values Significant
Before 
treatment 
Improvement 
after 
Treatment 
Difference
1. Pallor of 
skin and 
conjunctiva 
40.0 ± 
3.5777 
23.0 ± 2.6833 17.0 ± 
0.012 
27.386 P < 0.000 *** 
significant 
2. Loss of 
appetite 
34.0 ± 
3.5777 
29.0 ± 3.5777 5.0 ± 
0.982 
23.278 P < 0.001 *** 
significant 
3. Tiredness 37.0 ± 
4.4721 
28.0 ± 2.6833 9.0 ± 
0.338 
20.266 P < 0.000 *** 
significant 
 
 n = 40; values are expressed as mean ± S.D followed by student one 
sample ‘t’ test. 
 (***) P < 0.001 (**) P < 0.003 as compared with that of before and after 
treatment. 
 Thus the improvement in symptoms of pallor, loss of appetite and 
tiredness after treatment with Thaetran karpam is statistically significant. 
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DISCUSSION 
 Paandu remains one of the major global health problems, with higher 
prevalence in children and women of low socio-economic class. 
 According to Agathiar as mentioned in Agathiar attavanai vaagadam 
Thaetran karpam is used to treat paandu noi. 
 As per Siddha system Paandu noi is due to the derangement of Kabha 
Kutram. 
  ""uõß¬ÒÍ ÷\zx©¢ uõÛÍQÀ... 
   .... £õsk-'' 
  ""Pshõ÷¯õ ]÷»Ø£ÚzvÀ Áõu{õi 
   P»¢vkQÀ.... £õsk....'' 
  ""Ch©õÚ ÷\zx©zvÀ ¤zu {õi 
   ..... GÊ¢uÝQÀ... £õsk ÷µõP®'' 
 The taste of Thaetran (Strychnos potatoram seeds) is Kaippu (Vayu + 
Aagayam) and it has veppa veeriam. 
According to Kanusamiam 
 ""Áõu® ÷©¼mhõÀ ©xµ® ¦Î²¨¦ 
 ÷\u¬Óa ö\´²g ]øÓ²® KuU ÷PÒ 
 Põµ¢ xÁº P\¨¦ Põmkg _øÁ ö¯À»õ® 
 \õµ¨ £¶Põµg \õØÖ''              – Psq\õª¯®4 
 According to this verse, Karppu, Thuvarpu and  Kaippu Suvai balances 
the imbalanced Kabha kutram. So the Kaippu Suvai of thaetran equalises the 
imbalanced Kobha kutram. Morever Vayu bhootham is said to strengthen the 
body and enhance the general well – being of the human body. Thus Thaetran 
helps in treating paandu noi in a dual way. 
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 Pharmacognositic studies of the powder showed fragments of testa, 
trichomes, endosperm cells and oil globules. 
The antimicrobial study of Thaetran karpam shows it is sensitive to 
Staphylococcus aureus, E.coli, Klebsiella Pneumoniae, pseudomonas 
aeruginosa, streptococcus mutans. Patients with Paandu noi generally have 
lower immunity and they are susceptible to all opportunistic diseases. Theatran 
itself being a good anti microbial agent helps in protecting them from these 
infections.  
 Biochemical analysis of thaetran  showed the presence of calcium and 
iron. 
 Quantitative analysis shows the presence of 373.0 mg/kg of iron (Fe iron 
which is a very important constituent of haemoglobin and plays an important 
role in the formation of the haem part of haemoglobin. The iron in Thaetran 
helps in the haematopoetic functions of iron. 
 Phytochemical analysis shows the presence of steroids, proteins, 
alkaloids, glycosides, tanins, saponins and flavanoids. 
Bio flavonoides 
 Bio   –  ‘life’ (Greek) 
 Flavo   –  ‘flavouring agent’ yellow colouring pigments of 
fruits and flowers. 
 Oeides - ‘in the form’ (Greek)  
 Meaning  ‘life in  the form of yellow colouring agents’ 
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Flavonoides are very good antioxidants. American medical Association 
prescribes flavonoides as one of the important dietary supplements for 
anaemia. They promote the capillary resistance to haemorrhaging.30 
 Further studies on qualitative estimation of S.potatorum shows the 
presence of Alkaloids (1.3%), flavonoids (0.021%) phenols (0.059%) tanins 
(18.00%) and saponins (4.741%). 
 Good and well balanced nutrition is the basis for the proper functioning 
of the haematopoitic system. All such nutrients including steroids proteins and 
flavanoides are present in thaetran. So they play a role in enhancing the 
haematopoietic system. 
 Literature has shown that oral ingestion of any medicinal compound or 
drug can alter the normal range of haematological parameters. These alterations 
can be either positive or negative. In this study most of the effect recorded for 
the seeds of Thaetran karpam is positive44. 
 It is possible that it contains active principles like haematopoetic like 
principles (or) contain active biological principles stimulating haematopoitins 
(erythropoetin, leucopoetin, thrombopoetin). However isolation of active 
principles in extract and elucidation of their mechanism would constitute 
further studies. The active biological principle may be responsible for its 
haematopoetic effect. 
 Liver plays an important role in erythropoisis. Blood proteins for 
example clotting factors and albumins are produced in liver. Blockage of 
biliary system produces haemolytic anaemia and jaundice. Studies shows the 
very efficient hepatoprotective  activity of Strychnos potatorum. This may play 
a positive role in enhancing its use in Paandu noi. 
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 Karpa medicine of Siddha medicine are said to have very good 
antioxidant properties. Further Strychnos potatorum Linn. is a proven 
antioxidant. Studies  have shown that, in children with low haemaglobin level 
there is increased oxidant stress which may be the reason for platelet 
aggregation in them and antioxidants is widely used to combat the problem. 
Thus the antioxidant property of Strychnos helps reduced the oxidant stress and 
in turn the platelet aggregation.  
 Acute toxicity study shows Thaetran at the dose of 2000 mg/kg/p.o did 
not exhibit any mortality in rats. 
 The pharmacological study shows chronic administration of Thaetran at 
the dose of 500 mg/kg/p.o. showed significant increase in Hb% of animals with 
concurrent increase in RBC count. 
 The clinical study has been conducted on 40 patients. Among them, 23 
patients who had pallor of skin and conjunctiva showed good improvement at 
the end of 6 weeks. 29 patients developed good appetite within 2 weeks and 28 
patients who had fatigue and breathlessness showed good improvement in 4 
weeks. 
 Invariably most of the patients developed good appetite. Thaetran has 
stomachic and digestive properties according to siddha literature. This may be 
attributed to the increased absorption in the GI tract.  
 From the above studies Thaetran has been proved to be clinically 
effective against Paandu noi. 
 Overall results lend support to the literature evidence to use Thaetran 
karpam in Paandu. 
 Gradual withdrawal of the medication was done and the follow-up was 
done for 2 more weeks. 
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SUMMARY 
• The trial drug Thaetran karpam was selected for paandu noi based on 
evidence in siddha literature. 
• It is a herbal drug easily available, economical and preparation is 
simple. 
• The single drug was purified prepared as choornam and stored. 
• Pharmacognositcal study was carried in Central Research Institute 
for Siddha, Chennai – 106 and pharmacological studies were carried 
out in C.L. Baid Mehta College of Pharmacology Thorapakkam, 
Chennai. 
• Rf values were determined by T.L.C.  
• Phytochemical test showed the presence of alkaloids, sugar, steroids, 
proteins, tanins, phenols, flavonoids, saponins, aminoacid, 
glycosides and tannic acid. 
• Biochemical analysis showed the presence of calcium, iron. 
• Anti microbial study proved it to be an effective antibacterial agent. 
• Acute toxicity studies showed Thaetran did not exhibit any mortality 
in rats at 2000 mg/kg. 
• Animal experiments revealed that this drug is effective in improving 
the Hb and RBC levels in blood. It has good haematinic activity. 
• The administration of Thaetran karpam for 42 days did not produce 
any side effects. 
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• Clinical trials showed Thaetran is effective in raising Hb levels upto 
2 – 4 mg and effective in treating all the symptoms of paandu noi 
when treated for 48 days. 
• Out of 40 patients 32 showed better response in reductive of 
symptoms pallor, loss of appetite and fatigue. 
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CONCLUSION 
 Thaetran karpam has significant haematinic property in animal studies. 
Anti microbial studies shows it is potent anti-bacterial agent. From the clinical 
study it is concluded that Thaetran karpam moderately rises Hb and RBC levels 
and is clinically effective in treating Paandu noi. It did not produce any adverse 
effects during chronic administration. Thaetran karpam needs further study 
with regard to the mechanism of action to develop it as a potent haematinic 
agent. 
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INTRODUCTION 
 
 Infections of the Upper Respiratory Tract (URIs) have a tremendous 
impact on public health. They are among the most common reasons for visits to 
primary health care providers, and although the illness are typically mild, their 
high incidence and transmission rates place them among the leading causes of 
time lost from work or school. Non specific URI are a broadly defined group of 
disorders that collectively constitute the leading cause of ambulatory care, 
visits. 
 In this fast developing world, rapid growth of industrialization and 
globalisation inspite of their positive effect seem to take heavy toll on the 
health of human beings in various aspects. This rapid growth of industries and 
machineries pollute the atmosphere with a lot of toxic substances. With the 
change in dietary patterns and very high increase in pollution diseases 
especially of the respiratory system and allergies are on the rise. Peenisam is 
one such disease which is on sudden rise due to pollution and unhealthy dietary 
habits. 
Even though minority of cases are cause by bacteria, URI s are the 
leading diagnosis for which  antibiotics are prescribed largely. The enormous 
consumption of antibiotics for these illness has contributed to the rise in 
antibiotic resistance among common community acquired pathogens – a trend 
that in itself has had a tremendous impact on public health. 
With the more and more problems like resistance to antibiotics arise 
Siddha system of medicine provide the best alternative. 
 56
 One of the disease that falls under this category is Peenisam mentioned 
in Siddha literature. Though it is hardly ever fatal it is one of the most 
debilitating diseases that affects one's day to day activities. 
 The drug choosen is "Peenisa choornam" mentioned in Sarabendhirar 
Siraroga sigichai. The efficacy of the drug in treating the disease has been 
studied in the following work. 
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AIM 
 
 To evaluate the efficacy of Peenisa choornam in the management of 
Peenisam. 
OBJECTIVES 
 To subject the trial drug to phytochemical and biochemical analysis. 
 To study the antimicrobial activity of the drug. 
 To study the acute toxicity and pharmacological activity of the drug. 
 To ascertain the clinical efficacy of the drug for the management of 
Peenisam. 
 To analyse all the above study results to evaluate the efficacy of the 
drug. 
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REVIEW OF LITERATURE 
Solanum surattense11,48 
Family : Solanaceae 
Synonyms  : S.xanthocarpum 
Vernacular Names 
 Eng : Yellow berried nightshade 
 Hind : Kateli 
 Kan : Nelagulle  
 Sans : Kantakari, Nidigdhika 
 Tam : Kantattiri 
ACTION AND THERAPEUTIC USES 
 Anti-inflammatory, digestive, antihelmintic, diuretic, expectorant, 
febrifuge and aphrodisiac. Root is an expectorant used in the treatment of 
cough and asthma. 
Chemical constituents 
o A new sterol carpestrol benzoate, scopoletin, esculin, esculetin, 
solasodine, solasonine  solamargine and β solamargine isolated. 
 
o Pharmacological studies on this herb have been shown that aqueous 
and alcoholic extracts of the plant posses hypotensive effect which is 
partly inhibited by atropine;  
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o Both glycoalkaloid and fatty acid fractions of the extract cause 
liberation of histamine from chopped lung tissue. 
 
o The beneficial effect of the drug on bronchial asthma may be 
attributed to the depletion of histamine from bronchial and lung 
tissue and its expectoration action due to inorganic nitrate content. 
 
o Extracts of the whole plant show anti viral activity against Ranikhet 
disease virus and also sarcoma 180 in the mice.  
 
o Extracts of shoot and fruit show antibacterial activity against 
staphylococcus aureus and E.coli in phosphate buffer. 
 
Psh[Pzv¶ – Solanum Surrattense11 
÷ÁÖö£¯º 
 Psh[Pzv¶°ß ÷£º P¸uU ÷PÐ 
  Psh[Põ¶ xØ£g \õÁõS® 
 ¤shPõ ¤Ó¯v |vzv PõÁõ® 
  ¤Ó÷\õv }µõèiPõ PõÓoPõ ÁõS¢ 
 vshPõ][Q |èzvµ ÂµõuQ¶ 
  |\¨¤¶¯ ÁõÓuõQ Psh |¯õS® 
 ¬shPõ _Áõ\õU QÛ²©õS 
  ¬¯ºPsh[ Pzv¶°ß ÷£¸©õ÷© 
– ÷£õPº |Psk – 12007 
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 £¯ß£k® EÖ¨¦  :  Cø», §, Põ´m £Ç®, Âøu, ÷Áº 
 _øÁ   : Põº¨¦ 
 ußø©  : öÁ¨£® 
 ¤¶Ä   : Põº¨¦ 
 ö\´øP  : ÷PõøÇ¯PØÔ 
     ]Ö}º¨ ö£¸UQ 
     APmkÁõ´ÁPØÔ 
 Sn®  : Põ\ _Áõ\[ Pvzuñ¯  ©¢u©ÚÀ  
    Ã_ _µg \ßÛ ÂøÍ÷uõh® –B_Ö[PõÀ  
    Czuøµ² oØPõ G¶Põµg ÷\ºUPsh[  
    Pzv¶ ²s hõ©õQØ Põs. 
ÂÍUP® 
 CuÚõÀ Põ\®, _Áõ\®, ñ¯®, AUQÛ ©¢u®, wa_µ®, \ßÛ Áõu®, HÊ 
ÁøP ÷uõh[PÒ, Áõu ÷{õ´ BQ¯øÁ ÷£õ®. 
 Psh[Pzv¶ ÷Áøµ ¬øÓ¨£i Påõ¯ªmk, AvÀ v¨¤¼a `µn¬® ÷uÝ® ÷\ºzxU 
öPõkUP C¸©À, }º÷uõå® ¬u¼¯Ú _P©õ®. 
Psh[Pzv¶ ÷Áº Si}º 
 P¶¯ Psh[ Pzv¶÷Áº Põµ¬ÒÍ ]Ö÷uUS 
 ¬¶¯ ¬zuU Põ_h÷Ú ö¯õzu _USa ]Ö-»® 
 öu¶¯ Â¸£i }ºÂmka ]ÖPU Põ´a]U Si¨¥÷µÀ 
 u¶¯õ ÷uõk® Áõu_µ ö©ß÷Ó uµoU Søµ ö\ÆÁõ´  
(÷uµß – Si}º) 
 Psh[Pzv¶ ÷Áº, Psk£õµ[Q, ¬zuUPõ_ (÷PõøµQÊ[S) _US, ]ÖÁÊuø» 
÷Áº ¬u¼¯ÁØøÓ J÷µ AÍÂÀ Gkzx, Cµsk {õÈ uspºÂmk, GmiÀ JßÓõ´ 
ÁØÓUPõ´a] A¸¢vÀ Áõu_µ® |À»õx }[QÁk®. 
Psh[Pzv¶ ÷\¸® ©¸¢xPÐÒ ¥|\® }[S® ©¸¢xPÒ 
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1. |vUvPõv ÷»Q¯®21 
2. _Áõ\ Shõµ ÷»Q¯®21 
3. SUQÀ ö{´10 
Psh[Pzv¶ ÷\¸® ¤Ó ©¸¢xPÒ 
1. ]zuõ©À¼ Påõ¯®17 
2. v¶£»õz¯ Påõ¯®17 
3. Áõéõv Påõ¯®17 
4. ÷uÁuõºÁõv Påõ¯®17 
5. ÷\ÁPÚõº Gsön´17 
6. P¶¨£õø»z  ushõv Påõ¯®17 
7. ]®å¯õv Q¯õ©®16 
8. \õµøÍ ÁhP®22 
9. ]ÖPõg ö\õÔ Påõ¯®22 
10. ©Põ _uºåÚ `µn®22 
11. £g\vU uUQku®22 
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Rhus succedanea 
Family : Anacardiaceae 
Vernacular names 
 English  : The galls 
 Hindi & Bengali : Kakra – singi 
 Tel   : Kakeera - sryngi 
 Tamil   : Karkadaga singi 
 Kannada  : Karkata - shringi 
 Marathi  : Kakada  - shingi 
Parts used : 
Galls : Horn like galls are caused on the branch by some insects 
Action and therapeutic uses 
 The galls are reported to possess astringent, tonic, expectorant and 
stimulant properties. Used in treating diarrohea and dysentry in children. 
Chemical constituents 
 Gallotanin is the main polyphenol present in sapwood, fisetin, fustin, 
gallic and ellagic acids, garbanzol, sulfuetin are present. 
 Rhus flavone, amento flavone, agat hisflavone, cupressuflavone and 
mesuaferrones A and B isolated. 
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PºUPhP][Q – Rhus succedanea1 
÷ÁÖö£¯º : PºUPhP][Q, PØPõhP ][Q  
 PØPhP ][Q°ß ÷£º P¸uU ÷PÐ 
  Pk]Ô[P[SÎ[Põ Áõ[ PkUPõ´ §Áõ® 
 ÁØPhP® ÁUQÓõ\ ©Põ ÷PõåõÁõS® 
  Áõµ[Q Pg\¢vµõ\® ÂåÚõ\©õS 
 PØPhP ©Óu \õÁg \õÁuõS® 
  ©¸Â¯÷uõµ v\õµ¨ ö£¢v¯õS[ 
 PØPhP¢ xÁØ£õÚ £aø\ ÁÓÛ 
  P¸zöuÀ»õ[ PØPhP ][QUPõ÷© 
– ÷£õPº  |Psk 12007 
 _øÁ   : xÁº¨¦ 
 ußø©  : öÁ¨£® 
 ¤¶Ä   : Põº¨¦ 
 ö\´øP  : ÷PõøÇ¯PØÔ  
     öÁ¨£¬shõUQ 
     ö\¶¨¦shõUQ 
     ¤zu}º¨ ö£¸UQ 
xÁº¨¤ 
     Eµ©õUQ 
     Eh¾µ©õUQ 
 
 Sn®  : PºUPhP ][Q P£[Põ\® DøÍ 
    ö¯õ¸ ¬UPÀQµõo ¬v¶øµa\À– 
ö£õU öPÚ÷Á  
    \õkQßÓ ÷£vø¯²g \õ¸® \¶øÁ¯øµU  
    TkvÓ[ öPõUS[ TÖ. 
 CuøÚ Áõ°»hUQU öPõsk Cuß \õµzøu ÂÊ[P C¸©»h[S®. 
 Cøua \ºUPøµ²hß P»¢x EmöPõsk £õÀ AÀ»x }º A¸¢u 
ö£sPÐUSshõS® öÁÒøÍ |ØS®.  
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PØPhP][Q ÷\¸® ©¸¢xPÐÒ ¥|\® }[S® ©¸¢xPÒ: 
 P£õ» `ø», ¥ |\zxUS øu»®28 
PØPhP][Q ÷\¸® ¤Ó ©¸¢xPÒ 
1. Bhõ÷uõøh ö{´24 
2. ^µPõv CÍP®9 
3. ][Q{õu `µn®24 
4. Tè£õsh (§\o) ÷»Q¯®26 
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Clerodendrum serratum13 
Family : Verbenaceae 
Vernacular names 
 English  : Beetle killer 
 Hindi   : Bharangi 
 Kanada  : Gantabarangi 
 Malayalam  : Cerutekku 
 Sans   : Bharngi, Kharasakah 
 Tam   : Sirutekku 
 Tel   : Gantubharangi 
Action and therapeutic uses 
 Anti-inflammatory,  digestive, carminative, stomachic and anthelmintic 
expectorant, antispasmodic, stimulant. Used in dyspepsia, helminthiasis, skin 
diseases, cough, asthma, bronchitis, leucoderma. 
Chemical constituents 
 Et.OH (50%) extract of plant hypotensive. 
 Et.OH (50%) of aerial parts spermic and CNS depressant 
Studies on Clerodendrum serratum54 
 In vitro and in vivo immunomodulatory activity of aqueous extracts of 
clerodendrum serratum. roots. 
 The aqueous extract of Clerodendrum serratum has been investigated its 
immunomodulatory activity. The phytochemical screening revealed presence of 
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D-Mannitol, stigma sterols, three triterpenoids, oleionolic acid, queretaric acid 
cerrategenic acid. 
 Macrophages treated with the extract exhibited increased acid 
phosphatase and myeloperoxidase activity as well as significant increase in 
production of nitric oxide (NO) hydrogen peroxide (H2O2) and O2. 
Administration of CSAQ at doses of 100 and 200 mg /kg p.o in mice 
significantly increased carbon clearance index and ovalbumin induced delayed 
type hypersensitivity (DTH). 
]Ö÷uUS  – Clerodendrum serratum4  
÷ÁÖö£¯º : Psk£õµ[Q  
]Ö÷uUS¨ ÷£º 
 ]Ö÷uUQß ÷£ºuøÚ÷¯ ö\¨£U÷PÐ 
  ö\¯©õÚ öPØu£ \õug\©õS® 
 £Ö÷uUS¨ £µ[Q¨ £x¶¯õS® 
  £õ[PõÚ¨ ¤Óõ©Ú¯ åP©õP® 
 ©Ö÷uUS ¯õ[Põµ ÁÀ¼¯õS 
  ©ÇPõÚ _UQ©õuõ\©õS[ 
 PÖ÷uUS Põ\zv¨ £µ¬©õS[ 
  Põmi¯÷uõº ]Ö ÷uUQß PnUS©õ÷© 
– ÷£õPº |Psk 12007 
 £¯ß£k® EÖ¨¦ : Cø», ÷Áº 
 _øÁ   : øP¨¦, xÁº¨¦ 
 ußø©  : öÁ¨£® 
 ¤¶Ä   : Põº¨¦ 
 ö\´øP  : öÁ¨£¬shõUQ 
     uõx öÁ¨£PØÔ 
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Sn® : 
 CuÚõÀ ¬USØÓ®, Cøµ¨¤¸©À, EÒöÁ¨¦ öÁÔ÷{õ´, _µ®, -UQÀ 
¬ß}º÷PõøÁ, ¤ß }º÷PõøÁ, ¥|\® {õm£mh ÁÎ÷{õ´ SÎºPõ´a\À, EhÀÁ¼ 
EmPõ¢uÀ ©Úzuk©õØÓ® w¸®  
 Psö£õµ[Qö¯Ýg ]Ö÷uP Ss÷hÀ 
  Põö»[÷P ¤zuö©[÷P P£¢uõöÚ[÷P 
 öuõsöuõmkz öuõhº _Áõ\ Põ\ ö©[÷P 
  _µö©[÷P öÁÔ÷¯[÷P öuõÛ÷{õ ö¯[÷P 
 ªsk ¦¶ ¥{\}ºP ÷PõøÁ ö¯[÷P 
  öÁÎ}¸s pöµ[P ÂÓØPõ ö»[÷P 
 Asö£hõa ^u_µ[ Pk¨¦ ö©[÷P 
  ¯Çø»¯P ÷{õö¯[÷P ¯øÓS Ã÷µ! 
 Cuß ÷Áºö£õi, _USzyÒ CøÁPøÍ KµÍÁõP Gkzxz ÷uÛØ P»¢x 
öPõkUP, Cøµ¨¤¸©À w¸®. 
]Ö÷uUS ÷\¸® ©¸¢xPÐÒ ¥|\® }[S® ©¸¢xPÒ 
1. ¥|\zvØS® _Áõ\zvØS® Gsön´21 
2. Ska¯õv Påõ¯®17 
]Ö÷uUS ÷\¸® ¤Ó ©¸¢xPÒ 
1. ÷uÁuõºÁõv Påõ¯®17 
2. Áõé”õv Påõ¯®17 
3. ÷Põmhõv Påõ¯®17 
4. P¶¨£õø» ushõv Påõ¯®17 
5. xxÁøÍ¯õv Påõ¯®17 
6. _si¯õv Q¯õÇ®22 
7. £µ[Q¯õv Q¯õÇ®22 
8. ^µPõv CÍP®10 
9. |»USªÌ Phõ¯®17 
Picrorhiza kurroa23 
 68
Family : Scrophulariaceae 
Vernacular names 
 English  : Picrorhiza  
Sanskrit  : Katurka 
 Tamil   : Katukarogini 
 Bengali  : Katiki 
 Arab   : Khanekhaswad 
 Hindi   : Katuka, Kuru 
 Mal   : Katurohini 
Action and therapeutic uses 
 In small dose it is a bitter stomachic and laxative and in large doses a 
cathartic. It is reputed as an antiperiodic and cholagogue.  
Chemical constituents 
  Extracts increased bile flow in dog, alcoholic extract was effective in 
chronic carbon – tetrachloride induced hepatotoxicity, in rat. 
 Structure of kutkin isolated from roots, apocyanin, picroside also 
isolated. Crystattin kutkin shown to be a stable mixed crystal of picroside I and 
new glucoside- kutkoside. 
Hypolipemic effect of aqueous extracts of pilrorrhiza kurroa in 
hyperlipemic mouse model with hepatoprotective effect : A prevention 
study55 
Hypolipemic effect of the aqueous extract of P.kurroa was observed in 
high feeding hyperlipemic mouse at doses of 50, 100 and 200 mg/kg, orally 
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once a day for 12 weeks. Alanine transferase (ALT), low density lipoprotein, 
levels were significantly reduced for the treatment. On the contrary serum HDL 
level seems not affected by P.kurroa water extract. 
Anti carcinogenic study56 
 P.kurroa has shown to reduce formation of liver cancer due to chemical 
exposure in animal studies. Kutkin is a combination of active herbal 
constituents – Picrosides I, II and III and kuthoside kutkin’s antioxidant activity 
has been shown to decrease levels of lipid peroxidases and hydroperoxidases, 
free radical producing agents, and help facilitate the recovery of SOD, a 
powerful antioxidant in the liver needed to prevent oxidative damage. 
PkS÷µõQo  – Picrorrhiza Kurroa1 
÷ÁÖö£¯º : Pk÷µõQo, PhP ÷µõQo 
 PkS ÷µõPo ÷£¸ P¸uU ÷PÐ 
  P\£ ... \[Qß x¯©õ ÁõS[ 
 SkQ¯õ® ¤zu÷µõPo² ©õS[ 
  QÖån ÷£uõPsi¸Põ {õ-Úõ ÁõS® 
 ¯kS \P»õvÛ A÷Põ.... ÷µõPo 
  ¯õ©õ©U QÛ |ØP ÷µõPo ²©õP® 
 ÂkS Âå _¯¶¯õ® ÂzuUQÛ¯õS® 
  ÂÍ[Q¯÷uõ ÷µõPo°ß Â£µ©õ÷© 
      ÷£õP¬ÛÁº |Psk 12007 
 £¯ß£k® EÖ¨¦  :  ÷Áº 
 _øÁ   : øP¨¦, Põº¨¦ 
 ußø©  : öÁ¨£® 
 ¤¶Ä   : Põº¨¦ 
 ö\´øP  : ¬øÓ öÁ¨£PØÔ 
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     ö£¸[PÈa\¾shõUQ 
     £]zwysi 
     ShØ¦ÊÁPØÔ 
Sn® : 
 
 ©õ¢ug _µø©¯® Áõ²Pµ¨ £õÚõ©g   
 ÷\º¢u©»U Pmk v¶÷uõh®–÷£õ¢u ö£õmk¨  
 ¦sÁ°Ö ÷{õ°øÁ÷£õ® ö£õØöPõi÷¯ ÷£v²shõ®  
 vs PkS ÷µõPoUSz ÷uº. 
ÂÍUP® : 
 ©õ¢u®, _µ®, I¯¨ ö£¸US, Pµ¨£õß, ^zPÈa\À Á°ØÖÁ¼ ¦sPÒ, 
ÁÎ÷{õ´PÒ GßÝ® CøÁPÒ ÷£õ®. 
o Cuß ÷Áøµ ¬øÓ¨£i Si}¶mk vÚ® 3 AÀ»x 4 ÷ÁøÍ¯õP 3 – 4 {õmPÒ 
öPõkUP ÃUP® }[S®  
 
o \Ø÷ÓÓU SøÓ¯ 8 Qµõ® GøhyøÍ }¶À P»¢x \ºUPøµ ÷\ºzxU öPõkUP 
PÈ¯U ö\´²®. 
PkS÷µõPo ÷\¸®  ©¸¢xPÐÒ ¥Û\® }[S® ©¸¢xUPÒ! 
1. AµUS \¢uÚõvz øu»®24 
2. ¥Û\®A ©søhÁ¼, }ºÂÊu¾US -ÌPz øu»®21 
3. ¬ø»¨£õÀ Gsön´18 
4. SUQÀ ö{´10 
5. Põ£» Á¼USz øu»®19 
6. ÂÀÁõv øu»® (8 ÁøP ¥Û\® w¸®)25 
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PkS ÷µõQo ÷\¸® ¤Ó ©¸¢xPÒ 
1. öPõßøÓ÷uõÀ Påõ¯®17 
2. Ska¯õv Påõ¯®17 
3. ÷Põmhõv Påõ¯®17 
4. Pº¨£ C¸©À Q¯õÇ®18 
5. ©Põ _uº\Ú `ºn®20 
6. A_ÁP¢v £»õ»m\õz u°»®19 
7. ¤¨¤¶¯õv Q¸u®29 
8. \¢uÚõv øu»®17 
9. \P»Âu Qµ¢vPÐUS øu»®22 
10. PkS÷µõQo Gsön´22 
11. öPõ®£õUS øu»®22 
Nardostachys jatamansi 
Family : Valerianaceae 
Vernacular names 
 Sanskrit  : Jatamansi 
 Hindi   : Jatamansi 
 Bengali  : Jatamansi 
 Marathi  : Jatamavshi 
 Gujarati  : Jata mashi 
 Tamil   : Sadamanjil 
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Action and therapeutic uses 
 Antispasmodic, antipyretic, stimulant and diuretic. Used in the treatment 
of epilepsy and hysteria. Useful in intestinal inflammation, diseases of the 
blood and ulcers. 
Chemical constituents 
 Nardostachone, seychellene and seychelane, jatamasic acid isolated 
seychalane found to be a mixture of 2 epimers, norseychelanone, patchouli 
alcohol and  α- β patchoulenes, isolated from roots. Actinidine isolated from 
rhizomes. 
Studies on N.jatamansi  
 Cardio protective efficacy of N.jatamansi on mitochondrial respiration 
and lysosomal hydrolases was studied during Doxorubicin induced myocardial 
injury in rats. This could be mediated possibly through its antioxidant effect as 
well as by the attenuation of the oxidative stress.  
Anti convulsant activity 
 Ethanol Extract of the root of N.jatamans was studies for its 
anticonvulsant activity and neurotoxicity, alone and in combination with 
phenytoin in rats. The results demonstrated significant increase in the seizure 
threshold by Nardostachys jatamansi root extract against maximal electro 
shock seizures. 
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\hõ©õg]À 
Nardostachys Grandiflora 
÷ÁÖ ö£¯º 
 \hõ©õ], áh©õg], ø£\õ], \iø», ©õª] §u÷\ ]| 
 \hõ©õg]¨ ÷£ºuøÚ P¸vU ÷PÐ 
  Ph»i°ß ¦m©õ[Põ¸U SÍ®¦ 
 ÷uÓõ[S _©»Á[P ©õSg 
  ]Pµ ÷PÁ©õSg ]Á\¢uÚ ¦è£® 
 ÁÓõ®¦  ÁõQ¶ \®£®ã ¦è©õS® 
  Áõ¸zu ]ßÛ ¯õS ©¸Ä £õ[Qa] 
 uÓõ®¦ uõP\ªÛz uÍ©õg \zv 
  \vµõÚ Qµõ® ö£ßÖg \õzu»õ÷© 
–  ÷£õP  |Psk 12007 
 _øÁ  (£aø\°À) CÛ¨¦ 
  (Põ´¢u¤ß) Põº¨¦ 
 ußø©   –  öÁ¨£® 
 ¤¶Ä    –  Põº¨¦ 
 £¯ß£k® EÖ¨¦  –  ÷Áº 
ö\´øP  
 öÁ¨£¬shõUQ 
 C]ÁPØÔ 
 ]Ö}º¨ö£¸UQ 
 ÷PõøÇ¯PØÔ 
Sn® : CuØS  ]»¢v  {g_,  £øÇ¯ _µ®,  Em`k, Áõ´Ä, PÈa\À Ps÷nõ´ 
C¸©À Sµv¯ÇÀ, Cøµ¨¦ 
Smhg ]»¢vÂh®  ÷Põµ¦µõn _µ®   
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EmiÚ[PõÀ ÷£v Ps÷nõ´ Jmi¸©À & ö\õmiµzu  
¤zuªøµ¨ ÷£õS® ö£¸[÷Põøµ GßÝÓøµUSg  
_uu\hõ  ©õg]ø» ö\õÀ. 
 ^ø© CÚzøu¨ ö£õi ö\´x 10 & 20 SßÔö¯õøh }¶Ø P»¢x {õÒ JßÖUS  
Cµsk -ßÖ ¬øÓ öPõkUP, £øÇ¯ _µ®, `uP Á¼¨¦ }[S®. ¬UPõÀ 
ÁµõPöÚøh öPõkUP, ÷PõøÇø¯ öÁÎ¨£kzx®. 
 {õmk CÚzxa  \hõ©õg]ø¯ {_UQ, Cµsk ÁµõPöÚøh Gkzx Jº BÇõUS 
öÁ¢}¶À J¸ ©o ÷{µ® FÓøÁzx ÁiUPmi, AøµUPõÀ ¬uÀ Põ»õÇõUS 
Ãu® vÚ® ¬®¬øÓ öPõkzxÁµ, `ÇP \ßÛ Á¼¨¦ }[S®. 
\hõ©õg]À ÷\¸® ©¸¢xPÐÒ ¥|\® }[S® ©¸¢xPÒ 
1. \¸Áõ[P Gsön´25 
2. AµUS \¢uÚõv øu»®24 
3. ÂÀÁõv øu»®25 
4. Áõu÷\õou®, ¤zu®, uø»Á¼US {õ], Â¯õvUS  ¬ÌP Gsön´21 
\hõ©õg]À ÷\¸® ¤Ó ©¸¢xPÒ 
1. \¢uÚõv øu»®17 
2. ¬ø»¨£õö»sön´17 
3. Cµ\£u[P®9 
4. ©PõÂÀÁõv  CÍP®10 
5. ^µPõv CÍP®10 
6. öPõ®£µUS  øu»®22 
7. ]zuõ¬miz øu»®17 
Sodium chloride impura23 
 
Vernacular Names  
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Eng  : Rock Salt  
   Bay Salt 
   Sea Salt 
   Sodium Chlorate 
 
Arab  : Mil –he-Tabazard 
 
Sanskrit  : Saindhava 
 
Pension : Namaka – sang 
 
Hindi  : Sendhalon 
 
   Sedhalon 
 
Gujarati : Sindhaluna 
 
Telugu : Saindha lavanam 
 
Tamil   : Indu-uppu 
 
Malayalam : Inter – upper 
 
German : Natrium Chlorium 
 Characters : It is found as small white Crystalline grains or  
transparent cubes 
 
 It is brownish white externally and white internally. 
 
 It has a pure saline taste and burns with a yellow flame. 
 
Action and therapeutic uses 
 In small doses it is highly carminative stomachic and digestive. It 
promotes the appetite and assists digestion and assimilation.  
 In larger does it is cathartic, in large doses it is emetic. 
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 It is given in dyspepsia and other abdominal disorders. 
Sodium Chloride Impura2 
Rock  Salt 
C¢x¨§ 
÷ÁÖ ö£¯º  
ø\¢uÁ® 
]¢yµ® 
\¢vµÝ¨£¦ 
©v Tºø© 
©v²¨¦ 
ª¢uõa ö\õÀ 
\¢vµÝ¨¦ uÛzu ©vTºø© 
Bzvµ ÷Áø» ©¯VV®  £Ûø¯ 
©¢vµ® ÷£ õ»  Á¯º¢uµÂ¯¨¦ 
A¢vµ \õµ©õ®  C¢x¨¤ß ÷£÷». 
""\mh¬Û |Psk 1200 
 
øÁ¨¦ ¬øÓ  
 \¬zvµ }º, ¡Ö£iø¯ (200 ¼mhº) ¦xa\mi°À ÂmkU Põ´a] E¨ö£kzx, 
CÆÄ¨¤À ¡Ö £»® (3,800 Q) Ai PÚzv¸US® \mi°¼mk P¸®£õø» Ak¨¤ß «x 
øÁzxU PõhõUQÛ¯õÀ G¶UP E¨¦ E¸S®. Aa\©¯zvÀ öÁi²¨¦ 5 £»®. 
^ÚõUPõµ® 5 £»® §}Ö 3 £»® CøÁPøÍ ö£õizxz yÂ JßÖ£h E¸UQ SÎµ 
ÂmöhkUP Pmk®, Eøhzx¨ £õºUQÀ øÁµ® ÷£õ¼¸US®. CvÀ £aø\ PØ§µ® 
©i²®, §µ® ¬¨£õ®. Cx ©s §ua \µUPõS®.  
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_zv 
CuøÚ  Põi°À -ßÖ {õÒ FÓ¨÷£õmk , `¶¯ öÚõÎ°À E»ºzv GkUPa 
_zv¯õS®. Põi AÀ»x öÁÒÍõmk }¶À 3 {õÈøP ©zvzx öÁ´°¼À  E»ºzvU  
öPõÒÍ Cx _zv¯õS®. 
ö\´øP  
APmkÁõ´ÁPØÔ 
]Ö }º ö£¸UQ 
£]zwysi 
Sn® 
""AmhSn® ©¢u® A]ºUPµg`º ^u¤zu¢  
xmhøÁ¯® {õi¨¦s  ÷hõ[PÒ & öPmh ©»U  
PmkÂh Â¢øu¯U Põª¯ ÷{õ´ ÁßPµ¨£õß  
Âmk Âh Â¢x¨ø£ ÂÒ. 
ö\ßÛUPsnõ £Ø×º ö\ÂPÄÒPs h® £P ÷{õ´  
\¢v¯õ  \[PõP¢ uõP ªøµ¨ & ¦ßÛµzu 
-»g ]»¢v {Û -iP {g `øu Á¼ 
`»z ]øu²ª¢uõØ ö\õÀ. 
C¢x¨¤ÚõÀ Gs Âu Sß©®, A»\®,  A]ºUPµ®, P£¨¤zu®, P£õvUP®, 
{µ®¦UQµ¢v v¶÷uõå®, ©»£¢u®, Âå®, _UQ»®, PkÁß BQ¯ ÷{õ´PÒ, uø», 
ÂÈ, {õ , u¢u -»®, uõx, PßÚ®, Psh£®, ÷©õo CÆÂhzx ÷{õ´PÒ \¢|¯õ\® , 
÷{zvµ Põ\®, uõP®,  _Áõ\®,  Cµzu -»® ¬u¼¯ ¤oPÒ ]»¢v , ÷uÒ G¼ 
CÁØÔß Âå[PÒ , ÁõuUPk¨¦ `ø» ¬u¼¯Ú }[S®. 
÷uPzvÀ _ÐUS Á¢uõÀ C¢x¨ø£ £ØÖ ÷£õh»õ®. Á¼²hß Ti¯ 
ÃUP[PÐUS CøuU `hõUQ JØÓh® Ch»õ®; Cøu CÍg`hõÚ öÁ¢}¶À Pøµzx 
Áõ¢vø¯ Esk £snõ E£÷¯õQUP»õ®. 
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C¢x¨§ ÷\¸® ©¸¢xPÐÒ  ¤|\® }[S®  ©¸¢xPÒ 
1. _Áõ\ Shõ ÷»Q¯®18 
2. ¬ø»¨£õÀ Gsön´26 
C¢x¨§ ÷\¸® ¤Ó ©¸¢xPÒ  
1. Ska¯õv Påõ¯®17    
2. ÷\ÁPÚõº Gsön´17 
3. ÷©P{õu SÎøP19 
4. Pºnõªºu øu»®20 
5. Bhõöuõøh ö{´18 
6. ÂÀÁõv ÷»Q¯®22 
7. Tè£õsh (§\o) ÷»Q¯® 
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MATERIALS AND METHODS 
PREPARATION OF CHOORNAM 
Collection of the drug 
 The drug selected is Peenisa choornam as mentioned sarabendirar 
siragroga sigichai p.119. The raw drugs were all obtained from an indigenous 
drug store, chennai and identified by a botanist. 
Preparation and storage 
 The raw drugs Kadukurohini (Picrorhiza Kurroa), Sirutekku 
(Clerodendrum serratum), Karkadagasingi, (Rhus succedanea), Sadamanjil 
(Nardostachys Jatamansi), Kandangkathri (Solanum surrattense) were all 
washed infresh water to remove impurities, cleaned thoroughly and were 
allowed to dry in shade.  
 Rock salt was soaked in Kaadi neer for 3 days, dried in the sun and then 
powered. 
Preparation of Choornam 
 The dried drugs were all fried lightly and taken in the following 
quantities: 
 (P.Kurroa) Kadukurohini  - 3 parts 
 (R.succedena) Karkadasingi  - 3 parts 
 (Solanum Surrattense) Kandangkathiri - 1 part 
 (C. serratum) Sirutekku   - 1 part 
 (N. Jatamansi) Sadamanjil   - 1 part 
 (Rock salt) Indhuppu   -  1part 
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 They were then made into fine powder and sieved through a white cloth 
(Vasathira Kaayam). Then it was purified by steam cooking in milk (Pittavial 
method). The same was later powdered and sieved again and preserved. 
Storage of Choornam 
 The choornam was stored in a clean air tight container. 
Administration of the drug 
 Route of administration : Enteral 
 Dosage   : 1 gm twice a day 
 Vehicle   : Honey 
 Duration   : 48 days 
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ANTI MICROBIAL STUDY 
 
Method 
 
 The anti-microbial activities of different extracts of PEENISA 
CHOORNAM were studied by  Disc diffusion method against the following 
organisms. 
1. Staphylococcus aureus 
2. Escherichia Coli 
3. Candida albicans 
4. Klebsiella pneumoniae 
5. Pseudomonas aeruginosa 
Extracts of  Peenisa Choornam were used in the concentration of 100, 
50 and 25 µl using their respective solvents. Ciprofloxacin, (50 mcg/disc) used 
as standard. The disc diffusion method was employed for the screening of anti-
bacterial activity. 
Disc diffusion method 
 A suspension of organism was added to sterile soya bean casein digest 
agar media at 45°C, the mixture was transferred to sterile petridishes and were 
allowed tosolidify. Sterile discs, 5mm in diameter, dipped in solutions of 
different extracts, standard and a blank was placed on the surface of agar 
plates. The plates were left standing for one hour at room  temperature as a 
period of pre incubation diffusion to minimize the effects of  variation  in time 
between the applications of the different solutions. Then the plates were 
incubated at 37°C  for 18 hours and observed for anti-bacterial activity. The 
diameter of zones of inhibition were observed and measured. The average area 
of zones of inhibition were calculated and compared with that of standard's. 
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Zone of inhibition in mm 
Organism 
Standard 
drug 
ciprofloxacin 
50 mcg/disc 
Test drug (Peenisa choornam µl/disc) 
Zone of inhibition in mm 
25 µl 50 µl 100 µl 
Staph. aureus 29 13 18 20 
E.coli 28 15 17 18 
K.pneumoniae 30 12 18 19 
Ps aeruginosa 30 14 17 19 
C.albicans 32 15 18 22 
 
 Standard used for bacteria ciproflaxacin HCl, 5 mcg/disc. 
 Standard used for fungus ciproflaxacin HCl, 50 mcg/disc. 
Sample concentration 
 1.5 gm / 150 ml of solvent 
 25 µl, 50µl & 100 µl/disc. 
14 mm low sensitivity, 15mm: moderate, 16 mm & above : Highly 
sensitive  
Thaetran karpam was found to be highly sensitive to staph aureus, 
E.coli, K.pneumonia and  Ps aeruginosa. 
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Identification of the constituents of Peenisa Choornam by Phytochemical 
tests 
The drug powder and various extracts of Peenisa Choornam were  subjected to 
chemical tests for identification of its active constituents. 
Test for alkaloids 
 A small portion of the  solvent, free chloroform, alcoholic and aqueous 
extracts were treated separately with few drops of dilute Hcl and filtered. The 
filter may be tested carefully with alkaloidal reagents such as, 
 a. Mayer's reagent  - Yellow precipitate 
 b. Dragendroff's reagent - Orange brown precipitate 
 c. Wagers' reagent  - Reddish brown precipitate 
 
Test for Carbohydrates 
 Molisch's test 
 Filterate was treated with 2-3 days of 1% alcoholic alpha-napthol 
solution and 2 ml of concentrated H2SO4 was added along the sides of the test 
tube. Appearance  of brown ring at the junction of 2 liquids show the presence 
of carbohydrates. 
Test for Glycosides 
 Another portion of  Peenisa Choornam was hydrolysed with Hcl for few 
hours on a water bath and the hydrolysate was subjected to legal's Berntragers' 
test to detect the  presence of glycosides. 
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a. Legal's test 
 To the  hydrosylate, 1 ml of pyridine and few drops of sodium nitro 
prusside solution were added and then it was made alkaline with sodium 
hydroxide solution. Appearance of pink to red colour shows the presence of 
glycosides and aglycones. 
Test for phytosterol 
Lieberman burchard test 
 1 gm of the extract of Peenisa Choornam was dissolved in few drops of 
dry  acetic acid. 3 ml of acetic anhydride was added followed by few drops of 
concentrated sulphuric acid. Appearance of bluish green colour shows the 
presence of phytosterol. 
Test for saponins 
 The extracts of Peenisa Choornam was diluted with 20 ml of distilled 
water and it was agitated on a graduated cylinder  for 15 minutes. The 
formation of 1 cm layer of form shows the presence of saponins. 
Test for proteins and free amino acids 
 Small quantities of various extracts of Peenisa Choornam were 
dissolved in a few ml of water and treated with Hindryin reagent. Appearance 
of purple color shows the presence of proteins and free amino acids. 
Test for flavanoids 
 With aqeous sodium hydroxide solution the extract gives blue to violet 
colour if anthocyanins are present, yellow colour if flavones are present, 
yellow, to orange if flavanones are present. 
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Test for Tannic Acid 
 The extract is treated with ammonium molybdate and conc. HNO3, 
formation of blue black precipitate indicates the presence of tannic acid. 
Test for Tannins and Phenolic compounds 
 Small quantities of various extracts were taken separately in water and 
tested  for the presence  of  phenolic compounds  and tannis by adding  2 ml of 
10% lead acetate and 2 drops of FeCl3 solution. Presence of tanin and phenolic 
compounds is denoted by white precipitate and blue black colour respectively. 
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METHODOLOGY  FOR BIO-CHEMICAL ANALYSIS 
Preparation of extract 
 5 gm of Peenisa Choornam was weighted accurately and placed in a 250 
ml clean beaker and added with 50 ml of distilled water. Then it was boiled 
well for about 10 mins. Then it was cooled and fittered in a 100 ml volumetric 
flask and made upto 100 ml with distilled water. 
Test for Calcium 
 2 ml of extract was taken in a clean test tube. To this 2ml of 4% 
ammoniaym hydroxide solution was added. Presence of calcium is denoted by 
formation of a white precipitate. 
Test for Iron (ferric) 
 The extract was treated with glacial acetic acid and potassium 
ferrocyanide. Presence of  ferric iron is denoted by a blue colour. 
Test for sulphate 
 2 ml of the extract was added to 5% barium chloride solution. Presence 
of sulphate is denoted by formation of a white precipitate. 
Test for  Chloride 
The extract was treated with silver nitrate solution. The presence of 
chloride is denoted by formation of a white precipitate. 
Test for  Carbonate 
The extract was treated with concentrated Hcl. If carbonate  is present, it 
is denoted by effervescence. 
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Test for  Phosphate 
Te extract was treated  with ammonium molydate and conc. HNO3. If 
phosphate is present, it is denoted by the formation of a yellow precipitate. 
Test for unsaturation 
 1 ml of Potassium permangnate solution is  added to the extract. The 
presence  of  unsaturation is denoted by  decolourisation. 
Test for Iron (Ferrous) 
 The  extract was treated with conc. HNO3 and ammonium thiocyanate. 
(Presence of Ferrous iron is denoted by formation of a blood red colour) dilute 
ferric chloride solution (5%). The  formation of violet colour shows the 
presence. 
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Results for acid basic radicals and phytochemical screening for Peenisa 
choornam 
 The following constituents were present  
Acid radicals 
 Sulphate (trace) 
 Phosphate 
Basic radicals 
 Iron (Ferrous) 
Phytochemicals 
 Tannic acid 
 Sugar  
 Steroids (trace) 
 Proteins  
 Tannins 
 Phenols 
 Saponins 
 Aminoacid 
 Glycosides 
Miscellaneous 
Unsaturation present 
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Quantitative Analysis 
 
Equipment used : Atomic Absorption Spectrometer (AAS)  
Make : Varian, Australian 
 
Sl.No. Test Parameter Results 
01 Zinc as Zn 43.5 mg/kg 
02 Selenium as Se 110.0 mg/kg 
 
 
The sample had 43.5 mg/kg of Zn and 110.0 mg/kg of Se 
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PHARMACOLOGICAL STUDIES 
MATERIALS AND METHODS 
Preparation of drug for dosing 
 All drugs used for the study was suspended each time with 1% (w/v) 
solution of sodium carboxy methyl cellulose before administration. 
Drugs and chemicals 
 Histamine hydrochloride and fine chemicals used in these experiments 
were obtained from Sigma Chemicals company, U.S.A. Other analytical grade 
chemicals were obtained from S.d. Fine Chemicals Ltd., Mumbai. 
Experimental animals  
 Colony inbred animals strains of wistar rats of either sex weighing 200 – 
250 g were used for the pharmacological studies and Swiss albino mice of 
single sex weighing 20 - 25 g were used for toxicological studies. The animals 
were kept under standard conditions 12:12 (day/night cycles) at 220C room 
temperature, in polypropylene cages. The animals were fed on standard 
pelleted diet (Hindustan Lever Pvt Ltd., Bangalore) and tap water ad libitum. 
The animals were housed for one week in polypropylene cages prior to the 
experiments to acclimatize to laboratory conditions. The experimental protocol 
was approved by the Institutional Animal Ethical Committee (IAEC). 
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Acute oral toxicity study     
 
Acute oral toxicity was conducted as per the OECD guidelines 
(Organization of Economic Cooperation and Development) 423 (Acute Toxic 
Class Method). The acute toxic class method is a stepwise procedure with 3 
animals of a single sex per step. Depending on the mortality and /or moribund 
status of the animals, on the average 2-4 steps may be necessary to allow 
judgment on the acute toxicity of the test substance. This procedure results in 
the use of a minimal number of animals while allowing for acceptable data 
based scientific conclusion. 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) 
and the results allow a substance to be ranked and classified according to the 
Globally Harmonized System (GHS) for the classification of chemicals which 
cause acute toxicity 
Swiss albino mice of  single sex weighing 20-25 g were fasted 
overnight, but allowed water ad libitum. Since the formulation peenisa 
choornam is relatively non toxic in clinical practice the highest dose of 2000 
mg/kg/p.o (as per OECD guidelines “Unclassified”) was used in the acute 
toxicity study.   
The animals were observed closely for behavioural toxicity, if any by 
using FOB (Functional observation battery). 
Result for  Acute oral toxicity study 
PC at the dose of 2000mg/kg/po did not exhibit any mortality in rats. As 
per OECD 423 guidelines the dose is said to be “Unclassified” under the 
toxicity scale. Hence further study with higher doses was not executed.  
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Analgesic activity   
Tail Flick method 
 Withdrawal of tail (Tail Flick) for noxious thermal (radiant heat) can be 
used for screening drugs with analgesic activity. Radiant heat can be generated 
by passing electrical current through nichrome wire mounted in an 
analgesiometer. 
 Wistar albino rats of either sex weighing between 200 – 250 g were 
assigned into 3 groups of 6 animals each. Group I – received distilled water, 
Group 2 – received the standard drug diclofenac sodium, Group III – received 
the test drug peenisa choornam. 
 The base of the tail of the test rats is placed on a nicrome wire. The tail 
withdrawal for the radiant heat (flicking response) is taken as the end point. 
Normally the rats and mice withdraw their tails within 3 – 5 secs. A cutoff time 
of 10 – 12 secs is used to prevent damage to the tail. Any animal failing to 
withdraw its tail in 3-5 secs is rejected from the study.  
 The reaction time of test drug, standard and control are taken at intervals 
of 30, 60 and 120 mts. A reaction time (withdrawal time) increment of 2-5 secs 
more than the control animals can be considered for analgesic activity of the 
drug.  
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Table 
 
Analgesic activity of ( PC ) using Tail flick Plate Method 
 
Groups 
Paw flick response  (Sec) 
 
0 min 
( Sec) 
30 min 
( Sec ) 
60 min 
(Sec ) 
120 min 
(Sec) 
Control 2.266± 0.396 
 
2.293± 0.96 2.36±0.367 2.482± 0.653 
 
PC 2.266 ±  0.391 
 
3.083 ± 0.450 
*** 
4.533 ± 0.388 
*** 
5.103 ± 0.7995 
*** 
Standard dic. 
sodium 5 
mg/kg/po 
2.266 ± 0.391 3.53 ± 0.450 4.533 ± 0.388 5.803 ± 0.7995 
 
n=6,  Values are expressed as mean ± S.D using followed by paired T – test  
***P<0.001 as compared with control.  
Inference   
 The drug formula PC exhibited significant Analgesic activity (P<0.001) 
when compared to control in tail flick method. The analgesic response was 
exhibited only at the end of 60 and 120 mts after drug administration that may 
be due to the delayed absorption of the phytoconstituents responsible for the 
analgesic activity.  
 94
Anti inflammatory activity  
 Anti inflammatory activity was evaluated in acute model of 
inflammation.  
Acute model 
Carrageenan induced hind paw edema  
 The carrageenan assay procedure was carried out according to the 
method of Wintar et al. (1962). Wistar albino rats of either sex weighing 
between 200-250 g were assigned into 3 groups of 6 animals each. Group I – 
received distilled water, Group II – received standard drug dic. sodium, Group 
– 3 received the test drug peenisam choornam.  
 Edema was induced by injecting 0.1 ml of 1% solution of carrageenan in 
saline into the plantar aponeurosis of the left hind paw of the rats.  The extracts, 
reference drug and the control vehicle (distilled water) were administered 60 
min prior to the injection of the carrageenan. The volumes of edema of the 
injected and contra lateral paws were measured at +1, 3 and 5 hrs after 
induction of inflammation using a plethysmometer (Bhatt et al., 1977) and 
percentage of anti-inflammatory activity was calculated.   
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Anti inflammatory activity of  Peenisam choornam induced  
end paw edema in rats 
 
Groups Paw volume ( ml) by mercury Displacement at  
regular interval of time 
0min 30min 60min 120min 240min 15 hrs 
Control 
 
 
1.566 ± 
5.164 
1.883 ± 
7.528 
2.033 ± 
5.164 
2.183 ± 
7.528 
2.33 ± 
8.946 
2.516 ± 
9.832 
Peenisam 
choornam 
(500mg/kg. 
p.o.,) 
1.683 ± 
0.1472 ns 
1.808 ± 
0.1497ns 
2.0 ± 
0.303ns 
2.08 ± 
8.944*** 
1.85 ± 
0.197*** 
1.566 ± 
0.1366*** 
Standard 
(Dic.Sodium 
5 mg/kg/po) 
0.835 ± 
0.065*** 
1.315 ± 
0.069*** 
1.128 ± 
0.049*** 
1.011 ± 
0.056*** 
0.896 ± 
0.048*** 
0. 85 ± 
0.054 *** 
 
n=6; Values are expressed as mean ± S.D followed by paired T – test . 
ns - Non significant as compared with control; 
P< 0.000 (***) as compared with control. 
 
Inference 
In the acute phase inflammation model (carrageenan induced hind paw 
edema) PC showed significant (P<0.001) anti-inflammatory activity. In this 
study also the anti-inflammatory response was noticed at the end of 120 mts of 
administration whereas standard drug diclofenac sodium exhibited immediate 
response. This again may be due to the delayed absorption of the phyto 
constituents present in the drug from the intestine.  
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Antihistaminic activity 
Antagonistic action of PC in Guinea pig ileum contraction 
Histamine is an autocoid having many physiological effects in the 
system. Histamine has spasmogenic response in g.pig ilium. Histamine by 
acting on H1 receptor of smooth muscle causes contraction which can be 
recorded by a kymograph. Drugs  acting as H1 receptor antagonists, block the 
contraction of histamine in g.pig ileum. 
G.pig ileum is dissected out and placed in the watch glass containing 
Tyrode solution. Dissect out the ileum and clean the contents of the ileum by 
pushing the Tyrode solution into the lumen of the ileum. 
2 – 3 cm long ileum is taken and mounted to the tissue holder of the 
organ bath containing Tyrode solution maintained at 32 – 340C and bubbled 
with a mixture of CO2 + air.  
A tension of 0.5 g is applied to the lever and the tissue is allowed to 
equilibrate for 30 mts before adding drugs. Record concentration dependent 
response (10 μg – 80μg) due to histamine using a frontal writing lever. Add the 
test drug in different concentrations (2 μg - 5μg) to the tissue bath and repeat 
the concentration- response curve of histamine in the presence of the test drug. 
Calculate the % inhibition of contraction by the test drug.  
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Effect of the Peenisa choornam on histamine induced  
contractions of guinea pig ileum 
 
S. 
No 
Treatment 
Hista
mine 
μg/ml 
Mean 
contraction 
(M mol) 
Peenisa 
choornam 
µg/ml 
Mean 
contraction 
M mol 
% 
inhibition 
of 
Histamine 
Std. 
mepyramine 
1. 10.0 50.666 ±6.214 10.0 11.0 ±  
2.756*** 
22.0 
 
9.867 ± 0.875 
 
2. 20.0 55.5 ± 1.872 20.0 14.66 ±  
3.076*** 
26.3 
 
16.35 ± 2.182 
 
3. 40.0 61.0 ± 7.183 40.0 27.33±  
6.121*** 
 
44.7 
 
25.481 ± 4.312 
 
4. 80.0 64.50 ± 6.892 80.0 33.667 ±  
5.609*** 
51.5 
 
35.562 ± 6.213 
 
 
 n=6; Values are expressed as mean ± S.D followed by paired T – test 
*** (p<0.001) when compared with control. 
Inference 
 
Peenisa choornam showed antihistaminic activity when tested in guinea 
pig ileum. There was a dose dependent inhibition by Peenisa choornam on 
contractions of guinea pig ileum induced by histamine. The gradual 
antagonistic reduction on (in %) of the amplitude of contraction after dosing 
with 10, 20, 40 µg of Peenisa choornam was 34, 53, and 74.1 respectively 
against the amplitude of contraction with increasing dose of histamine (10-40 
µg /ml of bath).  
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CLINICAL ASSESSMENT 
 
The drug Peenisa choornam has been chosen to treat the disease 
Peenism.  
About the disease 
¥Ú\® 
÷ÁÖö£¯º  : }ºU÷PõøÁ, -UPøh¨¦ ÷{õ´, -US }º£õ´uÀ5 
1. -UQß xøÍUSÒ ]Á¢x x®©À 
2. Ps ]Á¢x }º ÁiuÀ 
3. -US }º £õ´uÀ 
4. uø» ÷{õuÀ 
5. AiUPi -UøPa ]¢v \Î, ^Ì, S¸v öÁÎ¯õuÀ 
GßÝ® SÔSn[PøÍ Eøh¯x. 
÷{õ´  ÷uõØÖÁõ´:  ªUP SÎº¢u  }øµ¨ £¸SuÀ,  £Û AÀ»x SÎº¢u  
PõØÔ½k£hÀ uÚUöPõÆÁõ¨¦øP, ¦Êv Ti¯ PõØÖ, x®©ø» EshõUPUTi¯  
ö£õ¸ÒPÍõÚ  CÁØøÓ ¬Pº¢uõ¾®, EhÀ öÁ¨£©øh¢xÒÍ ÷£õx \÷µö»Ú I¯zøu 
ö£¸UPUTi¯uõÚ SÎº¢u  }¶À uø» ¬ÊPÀ, SÎºa] u¸® ö£õ¸ÒPøÍ EmöPõÒÍÀ 
BQ¯ÁØÓõ¾®  C¢÷{õ´ ¤ÓUS®. AßÔ²® ÷©P ÷{õ´USz xøn¯õ´ C¢÷{õ´ 
Á¸Áxsk. 
 ÷¯õP |ø»°¾ÒÍ ÷£õx RÌÁõ´PÚÀ ußÚÍÂØS ªS¢öuÊ¢x  uø»  -øÍ 
Áøµ°Ø £õ´¢x B[S öÁ¨£zøu ²shõUQ -US ÷{õø¯ EshõUSö©Ú TÖÁõ¸¬Íº. 
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¬ØSÔ 
1. -UQö»õ¸ÁøP G¶a\¾®  {ø©²shõ´ 
2. AuøÚ uõ[P ¬i¯õx, -US  ¬øÚø¯ ÷u´zx ]ÁUP ö\´x ¤ß 
3. Ps  ]Á¢x Pspº ÁiuÀ 
4. -UPøhzuõØ ÷£õÀ ÷£\a ö\´uÀ 
5. PõuøhzuÀ 
6. PõvÀ {ø©a\¾shõuÀ. 
7. uø» ÷{õ´ 
8. -a_ EÒ Áõ[PÄ®, öÁÎ¯õUPÄ® ¬i¯õø© GßÝ® CUSÔPøÍ Põmi 
9. -UQ¼¸¢x uõÚÔ¯õ©÷» £Û }º ÷£õÀ ö\õmk®. 
÷{õ´ Gs 
 C¢÷{õ°øÚ  ]» ¡÷»õº Gs£zuõÖ GÚÄ® £vöÚmöhÚÄ® ÁS¨£º. uªÌ 
¡÷»õº CuøÚ ÁÎ, AÇÀ, I¯-UPøh¨¦, }º -UPøh¨¦, S¸v, ¬UPøh¨¦, ^Ì -UPøh¨¦, 
]µõ´ -UPøh¨¦, ¬øÍ -UPøh¨¦ PÊzx  -UPøh¨¦ Jß£uõP ÁSzxÒÍÚº. 
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SELECTION OF PATIENTS 
 The clinical study for the disease Peenisam was carried out in the out 
patient department of Arignar Anna Govt. Hospital of Indian Medicine and 
Homeapathy, Arumbakkam, Chennai. 
 40 cases from both the sexes of varying age group were selected. 
Including criteria 
1. Rhinitis 
2. Sneezing 
3. Nasal congestion 
4. Pain – PNS 
Excluding criteria 
1. Opthalmic headache 
2. Migraine 
3. Septal deviation 
4. Middle ear infection – otitis media 
Withdrawal criteria 
1. Irregular treatment 
2. Irregular visit 
Study design 
 Open clinical trial 
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Enrollment and method of study 
 Patients with the above inclusion criteria was enrolled in the study after 
recording the basic parameters date and time 1 g of Peenisa choornam with 5 
ml of honey was given twice a day after food for a duration 48 days. The 
patients were adviced to visit once in seven days for follow up and general 
observation, related to dose adaptation. Parallel clinical parameters were 
recorded. 
 The efficacy followup was taken at the end of 48 days.  
Treatment schedule 
 Peenisa Choornam – 1 g twice a day after food  
 Vehicle – 5 ml of honey for 6 weeks 
 Duration - 48 days 
Investigation 
 Blood routine 
 TC 
 DC 
 ESR 
 Hb 
X-ray - PNS 
Diet and medical advice 
1. The patients were advised to avoid known allergens 
2. Avoid smoking, cold stuff known allergic and irritating smells 
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3. To avoid cold, damp climate and advised precautionary measures to 
be taken in cold climates. 
Observation and results of clinical study 
1. Age 
2. Sex 
3. Socio – economic status 
4. Personal habits 
5. Occupational status 
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Age Distribution 
Sl.No. Age in Years No.of Patients Percentage % 
1. 11 – 20 6 15 
2. 21 – 30 16 40 
3. 31 – 40 9 22.5 
4. 41 – 50 9 22.5 
 
 
 
Inference 
 Among 40 patients, 40% of the cases lie in the age group of 21 – 30, 
20% of cases belong to the age group of 31 – 40 and another 20% belong to the 
age group of 41 – 50 age group while 15% belong to the age group 11 – 20. 
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Sex Distribution 
Sl.No. Sex No.of Patients Percentage % 
1. Male 15 37.5 
2. Female 25 62.5 
 
 
 
Inference 
 Among 40 patients 15 (37.5%) were male and 25 (62.5%) were female. 
The table shows women more prone to peenisam than men. 
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Habit distribution (in Men) 
Sl.No. Habit and Diets No.of Patients Percentage % 
1. Smokers Alcoholics 10 66.5 
2. Non – smokers 5 33.5 
 
 
Inference 
 Among men who had sinusitis 66% were smokers and 33% were non 
smokers. Smokers seemed to be prone to sinusits. 
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Occupation wise distribution 
Sl.No. Occupation No. of cases Percentage 
1. Homemakers 17 42.5 
2. Labourers 7 17.5 
3. Sedentary workers 6 15 
4. Software engine 4 10 
5. Student 6 15 
 
 
Inference 
 Occupation seemed to have a strong influence in peenisam. A major 
chunk is formed by People who do sedentary jobs especially people dealing 
computers eg. software engineers and computer mechanics. 
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Symptom wise distribution 
Sl.No. Symptoms Before treatment
After 
treatment Improvement 
Percentage 
% 
1. Sneezing 36 14 22 61.11 
2. Rhinitis 39 6 33 84.6 
3. Nasal 
congestion 
25 6 19 76 
4. Pain – PNS 37 12 25 67.56 
 
 
Inference 
 In the 40 patients, among 36 who had sneezing, 22 should good 
improvement. Among 39  who had Rhinitis, 33 should good improvement, 
among 25 who had Nasal congestion, 19 should good improvement, among 37 
who had pain in the PNS, 25 should good improvement. 
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Gradation of result 
Sl.No. Grade No.of Patients 
Percentage 
% 
1. Good 30 75 
2. Moderate 5 12.5 
3. Mild 5 12.5 
 
 
Inference 
 Patients who showed improvement from symptoms like rhinitis, nasal 
congestion sneezing and PNS pain within 3 weeks were considered to be 
having good improvement.  
Patient who showed improvement in 2 -3 symptoms after 4 weeks were 
considered to be having  moderate improvement. 
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Patients who showed improvement in one or 2 symptoms after 6 weeks 
were considered to be having mild improvement. 
Among the 40 cases, 75% cases show good improvement, 12.5% of 
cases show moderate results, 12.5 of cases show mild, results. 
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Statistical analysis of subjective parameters observed before and after 
treatment of patients 
S.No. Parameter 
Percentage 
Statistical 
test 
criterion 
Probability 
values Significant
Before 
treatment 
Improvement
After 
Treatment 
Different
1. Sneezing 36.0 ± 
5.3666 
22.0 ± 3.5777 14.0 ± 
0.012 
16.432 P < 0.000 *** 
significant 
2. Rhinitis 39.0 ± 
6.2610 
33.0 ± 4.4721 6.0 ± 
0.327 
15.258  P < 0.001 *** 
significant 
3. Nasal 
congestion 
25.0 ± 
4.4721 
19.0 ± 4.0332 6.0 ± 
0.327 
13.693 P < 0.000 *** 
significant 
4. Pain – 
PNS 
37.0 ± 
4.4721 
25.0 ± 2.6833 12.0 ± 
3.323 
20.266 P < 0.000 *** 
significant 
 
 n = 40; values are expressed as mean ± S.D followed by student one 
sample ‘t’ test. 
 (***) P < 0.001 (**) P < 0.003 as compared with that of before and after 
treatment. 
 Thus the improvement in symptoms sneezing, rhinits, nasal congestion 
and pain in the PNS after treatment by Peenis a choornam is statistically 
significant. 
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DISCUSSION 
 According to Sarabendirar siraroga sigichai Peenisa choornam is used to 
treat peenisam. 
 "£s£õÚ ¤zuzvÀ ÷\zx© {õi3 
 £¶]zuõÀ... 
   ... ¥Û\¬®'' 
 ""JkUP©õg ]÷»Ø£Ú {õi 
 ö¯õ¬[ öPõk.... 
   .... ¥Û\[PÒ''  
""Âµn¬hß ¦s¦øµUS Áõu¤zu® 
Âv¯Ô¯õ¨ ¥Û\¢uõß ¤zu÷\zx©®''  
     (£¶§µn {õi) 
¤zu I¯ P»¨¦ {õiPÎ¾® 
I¯ {õi ªQÝ®, 
¥Û\zøu SÔUS® 
 xÁº¨¦, øP¨¦ CÆÂµsk _øÁPÐ® ¤zu®, I¯® BQ¯ Cµsk SØÓ[PøÍ²® 
\©ß£kzx®. ÷©¾® Põº¨¦ ¤zuzøu²®, CÛ¨¦ I¯ªSvø¯²® \©ß ö\´²®. 
 Põº¨¦ _øÁ²øh¯ Psh[Pzv¶ I¯zøu \©ß ö\´²®. ÷©¾® CuØS 
÷PõøÇ¯PØÔ ö\´øP EÒÍx. 
 Psk£õµ[Q øP¨¦, xÁº¨¦, _øÁ²øh¯x, CÆÂµsk÷©, I¯zøu²®, ¤zuzøu 
\©ß ö\´²® ö\´øP Eøh¯x. 
 øP¨¦ _øÁ²øh \hõ©õg]À ¤zuzøu²® I¯zøu²® \©ß ö\´²®. ÷©¾® Cx 
÷PõøÇPØÔ ö\´øP Eøh¯x. xÁº¨¦ _øÁ²øh¯ PØPhP][Q ¤zuzøu²®, I¯zøu²® 
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\©ß ö\´²®. PkS ÷µõQo°À EÒÍ Põº¨¦ _øÁ ¤zuzøu²®, øP¨¦ _øÁ I¯zøu²® 
Cµsøh²® \©ß ö\´²®. 
 The anti bacterial activity of Solanum surrattense has been proved 
against E.coli, S.aureus. It accounts for the antibacterial activity of Peenisa 
choornam.  
 The anti microbial study of Peenisa choornam shows it is highly 
sensitive of E.coli, candida albicans, Klebsiella penumoniae, staphylococcus 
aureus and pseudomonas areuginosa. 
 The bacteria most often responsible for acute suppurative sinuisitis are 
staph aures, kleb pneumonia, H. influenzae, Peenisa choornam is highly 
effective for most of these organisms. So it is a highly effective antimicrobial 
agent for peenisam. 
 Biochemical and phytochemical analysis shows the presence of phenols, 
tannins, glycosides, trace of steroid, iron, phosphate and tannic acid. 
 Quantitative analysis shows the presence of zinc and selenium which are 
highly effective antioxidants used in the treatment of peenisam. 
 Acute toxicity study shows Peenisa choornam at the dose of 2000 
mg/kg/p.o did not exhibit any mortality in rats. 
 Pharmacological study shows Peenisa choornam showed significant 
inhibition of histamine induced contraction of g.pig ileum and have significant 
anti-inflammatory and analgesic properties. 
 Its anti – inflammatory and analgesic properties possibly effectively 
heals the inflammed sinuses and nasal passages and is responsible for the 
reduction of pain in paranasal sinuses.  
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 Allergic symptoms like sneezing and rhinitis are due to histamine 
Peenisa choornam has effective anti-histaminic action that reduces these 
symptoms. Solanum surrattense one of the constituents of peenisa choornam 
has been proved for its anti-histaminic activity. 
During the clinical study, among men 66% who showed better 
improvement were non smokers and the rest were smokers. 
This may be due to impaired ciliary movement and thickening of 
secretions. An adult produces approx. one litre of mucus a day in the nose and 
sinuses, most of which is carried through the nasal passages backward and then 
swallowed. 
This constant cleansing mechanism is facilitated by microscopic hairs 
called cilia. Cigarette smoke slows down the sweeping action of cilia. The thin 
mucus blanket that covers the nose and sinus lining thickens and post nasal 
drainage can become quite thick and noticeable. Smokers are less likely than 
non smokers to have the same degree of prognosis after treatment.  
Occupation did seem to have a strong influence on the disease. A 
considerable percentage was formed by software engineers and  computer 
mechanics. This would have been due to allergens accumulated in the closed 
air-conditioned rooms. Uncleaned carpets and furniture’s in the room and the 
uncleaned air filteres of these rooms are said to trigger these symptoms in a lots 
of patients (This is also referred to as “sick building syndrome”). The immuno 
modulatory effects of Clerodendrum serum  a constituent Peenism choornam 
possibly plays a role in enhancing the body’s defence mechanism against these 
day to day allergens.  
The clinical study has been conducted on 40 patients. Among them, 
among the patients who had sneezing 61% showed good improvement. 
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Among the patients who had Rhinitis 84.6% showed good improvement. 
Among the patients who had nasal congestion 76% showed good result. 
Among those who had the pain in the paranasal sinuses 67% showed 
good improvement. 
From the clinical study peenisa choornam was found to be effective in 
treating all the symptoms of peenisam. 
The results of the above studies support the literature evidence that 
peenisa choornam is an effective drug in treating peenisam.  
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SUMMARY  
• Peenisa choornam was selected to treat peenisam based on evidence in 
Siddha literature. 
• All the constituents are easily available in the market, economical and 
the preparation is simple. 
• The drug  was purified prepared as Choornam and stored. 
• Pharmacological studies were carried out at C.L. Baid Mehta college of 
pharmacology, Thorapakkam, Chennai. 
• Phytochemical and biochemical analysis shows the presence of 
phosphate , tannic acid, iron trace of sulphate, sugar and steroids, 
proteins, tanins, phenols, saponis, aminoacid and  
• Antimicrobial study proved it to effective against strep. pyogenes, staph 
aureus, K.pneumonia, P. aeruginosa and candida albican.  
• Acute toxicity studies shows peenisa choornam did not exhibit any 
mortality in rats. 
• Animal experiments proved that the drug has significant anti-histaminic, 
anti inflammatory  and analgesis properties. 
• Clinical trial showed peenisa choornam is effective in treating symptom 
like sneezing, rhinitis, nasal, congestion and pain of paranasal sinuses. 
• Out of 40 patients 33 showed good improvement. 
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CONCLUSION 
Peenisa choornam has significant anti-inflammatory analgesic and anti-
histaminic activity in animal studies. Anti microbial studies shows it has potent 
antibacterial and antifungal activity.  Evidences above and clinical study 
conclude beyond doubt that Peenisa choornam is clinically very effective in 
treating peenisam. Peenisa choornam needs further studies with regard to the 
mechanism of action to develop it as a potent anti-hisaminic.  
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 II A – CROSS SECTIONAL MICROSCOPIC VIEW OF  
Strychnos potatorum seeds 
 
 Fig IA  - Plant 
Fig II A - T.S of seed – outer region 
 B - T.S. of seed – middle region 
 C - T.S of seed  - central region 
 D - T.S of seed showing testa & trichomes 
 E - Middle region – enlarged showing endosperm cells 
 F - Central region – enlarged 
 
Abbreviations 
 Ie - Inner endosperm 
 Oe - Outer endosperm 
 Scl - Sclerendryma cell 
 Tr - Trichome 
 
Strychnos potatorum 
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ANTI MICROBIAL STUDY 
ZONE OF INHIBITION 
           E.coli    kl.pneumoniae 
 
 
 
 
 
     C.albicans               St. aureus 
 
 
 
 
 
PS. aeruginosa 
 
 
  
TLC of Strychnos potatorum 
 
 λ 254 nm     λ 366 nm     With spray reagent 
       Sodium Chloride impura                    Rhus succedenae 
 
 
 
 
 
 
 
 
 
 
 
 
           Nardostachys jatamansi                   Picrorrhiza Kurroa 
 
 
 
 
 
 
 
 
 
 
 
            Clerodendrum serratum          Solanum surrattense 
 
 
 
 
 
 
 
 
 
 
 
 
Peenisa choornam 
 
 
 
 
 
 
Anti Histaminic Activity 
 
 
IA – Strychnos potatorum 
OBSERVATION AND RESULTS 
CLINICAL STUDY ON PEENISA CHOORNAM IN THE MANAGEMENT OF PEENISAM 
 
Sl. 
No. 
OP 
No. 
Name Age 
/Sex 
Complaint Duration BT 
AT 
Investigation Result 
Blood Se Urine Xray 
PNS TC 
cell/cu.mm 
DC % ESR  Hb Sug Urea CL Sug Alb Dep 
P L E ½ 1 
1. 3642 Thiripura 
Sundari 20/F 
Sneezing, 
Rhinitis 
nasal 
congestion 
PNS pain 
present 
12.11.07 
24.12.07 
BT 10,000 64 32 4 4 9 10.5 87 18 157 Nil Nil Occ. 
pus 
cells 
Bilateral 
maxillary 
haziness–
Bilateral 
maxillary 
sinusits 
 
Sneezing 
and 
congestion 
absent 
Rhinitis and 
pain 
present 
AT 9,900 56 30 4 4 7 10 85 17 155 Nil Nil Occ. 
pus 
cells 
2. 3598 Kumaresan 
19/M 
Pain PNS 
sneezing 
nasal 
congestion 
present 
2.11.07 
20.12.07 
BT 9,700 59 34 7 15 34 10 88 18 157 Nil Nil Occ. 
pus 
cells 
Frontal 
haziness – 
Frontal 
sinusitis 
 
Congestion 
pain and 
sneezing 
reduced 
AT 9,500 56 30 5 10 30 9.5 80 19 159 Nil Nil Occ. 
pus 
cells 
3. 3948 Sathika 15/F Rhinitis 
nasal 
congestion 
PNS pain 
present 
3.11.07 
4.1.08 
BT 10,800 58 35 7 9 23 11.8 78 16 152 Nil Nil Few 
epi 
cells Maxillary 
sinusitis 
Congestion 
pain and 
rhinitis 
absent 
AT 10,000 52 34 6 7 20 12 80 17 154 Nil Nil Few 
epi 
cells 
4. 6313 Devi 31/F Nasal 
congestion 
and pain 
PNS present 
12.11.07 
4.2.08 
BT 10,700 63 30 7 12 20 11 95 16 148 Nil Nil 2-4 
epi 
cells 
Left maxillary 
haziness - left 
maxillary 
sinusitis 
Congestion 
moderately 
reduced 
pain absent 
AT 9,900 59 30 5 10 20 11.5 89 15 150 Nil Nil Occ. 
Pus 
Cells 
5. 953 Nirmal 26/M Sneezing 
PNS pain, 
rhinitis 
present 
26.11.07 
21.1.07 
BT 9,200 58 34 8 12 25 9 92 18 149 Nil Nil Occ. 
Pus 
Cells 
Bilateral 
maxillary 
haziness – 
Maxillary 
sinusitis 
Sneezing 
pain rhinitis 
reduced AT 9,000 54 32 5 12 20 9.5 90 17 154 Nil Nil Occ. 
Pus 
cells 
6. 1611 Mary  
42/F 
Sneezing, 
pain (PNS) 
rhinitis 
present  
27.11.07 
31.1.08 
BT 10,200 63 31 6 4 30 10 89 16 150 Nil Nil Occ. 
Pus 
Cells 
Bilateral 
maxillary 
Haziness – 
maxillary 
sinusitis 
Sneezing 
present 
PNS pain 
reduced 
AT 10,000 54 30 5 10 20 9 90 15 152 Nil Nil Occ. 
Pus 
Cells 
Sl. 
No. 
OP 
No. 
Name Age 
/Sex 
Complaint Duration BT 
AT 
Investigation Result 
Blood Se Urine Xray 
PNS TC 
cell/cu.mm 
DC % ESR  Hb Sug Urea CL Sug Alb Dep 
P L E ½ 1 
7. 1626 Lakshmi 
40/F 
Rhinitis, 
sneezing, 
congestion 
pain PNS 
present 
27.11.07 
22.1.08 
BT 10,300 62 34 4 15 34 10.5 122 18 147 Nil Nil Occ. 
Pus 
Cell 
Maxillary 
haziness - 
maxillary 
sinusitis 
Rhinitis 
present 
congestion 
reduced 
AT 10,200 60 36 5 20 40 9.5 110 19 152 Nil Nil Few 
epi 
cells 
8. 1913 Lakshmi 
50/F 
Sneezing, 
nasal 
congestion 
and PNS 
Pain present 
28.11.07 
20.2.08 
BT 9,800 60 34 6 20 47 10 115 17 152 Nil Nil Few 
epi 
cells Right maxillary 
sinusitis 
Congestion 
sneezing 
reduced 
PNS pain 
present 
AT 9,500 54 32 4 10 20 10 120 19 154 Nil Nil Few 
epi 
cells 
9. 1983 Geetha  
27/F 
Sneezing, 
Rhinitis, 
nasal 
congestion  
pain PNS 
present  
28.11.07 
31.1.08 
BT 10,000 64 31 5 12 20 11 135 20 149 Nil Nil Occ 
pus 
cells 
Bilateral 
maxillary 
haziness – 
Bilateral 
maxillary 
sinusitis 
Sneezing 
reduced 
congestion 
present 
AT 9,000 52 30 4 10 15 10 140 18 148 Nil Nil Few 
epi 
cells 
10. 1946 Usha 
30/F 
PNS pain 
nasal 
congestion 
Rhinitis 
28.11.07 
24.7.08 
BT 9,700 58 35 7 4 7 10 110 16 150 Nil Nil Occ 
Pus 
cell 
Frontal and 
bilateral 
maxillary 
sinusitis 
Congestion 
reduced 
pain 
present 
AT 9,400 52 31 5 10 20 10 120 15 147 Nil Nil 1-2 
epi 
cells 
11. 3126 Vasantha 
48/F 
PNS pain 
and 
congestion 
present 
1.12.07 
18.1.08 
BT 9,000 53 42 5 5 12 9 90 19 137 Nil Nil Occ. 
pus 
cells Bilateral 
maxillary 
sinusitis 
Pain and 
Congestion 
absent AT 9,100 50 34 5 10 20 8.5 120 18 140 Nil Nil Occ. 
pus 
cells 
12. 3181 Menaka 
25/F 
Sneezing, 
Rhinitis 
nasal, pain 
PNS 
congestion 
present  
1.12.07 
26.2.08 
BT 9,500 54 30 4 8 15 9.5 140 17 145 Nil Nil Occ 
pus 
cells Bilateral 
frontal sinusitis 
Sneezing 
and rhinitis 
reduced 
congestion 
present 
AT 9,300 57 38 5 10 15 10 125 19 157 Nil Nil Occ 
pus 
cells 
Sl. 
No. 
OP 
No. 
Name Age 
/Sex 
Complaint Duration BT 
AT 
Investigation Result 
Blood Se Urine Xray 
PNS TC 
cell/cu.mm 
DC % ESR  Hb Sug Urea CL Sug Alb Dep 
P L E ½ 1 
13. 5242 Vasanth 
24/M 
Sneezing 
congestion 
PNS pain 
present 
7.12.07 
26.2.08 
BT 9,400 57 39 4 2 3 9 210 17 152 Nil Nil Occ 
Pus 
cells 
Left maxillary 
haziness – left 
maxillary 
sinusitis 
Pain 
congestion 
and 
sneezing 
reduced 
AT 9,300 54 32 5 5 10 10 125 18 155 Nil Nil Occ 
pus 
cell 
14. 5252 Amudha 
33/F 
Pain PNS 
sneezing 
rhinitis 
present 
7.12.07 
21.2.08 
BT 10,100 64 32 4 20 44 10.5 110 19 140 Nil Nil Occ 
Pus 
cell Bilateral 
maxillary 
sinusitis 
Pain rhinitis 
relieved 
sneezing 
present 
AT 9,800 51 30 4 15 30 10 90 17 138 Nil Nil Occ 
Pus 
cell 
15. 5559 Logeshwari 
20/F 
Pain PNS 
rhinitis nasal 
congestion 
present  
8.12.07 
26.2.08 
BT 9,700 58 36 6 5 9 10.5 200 19 155 ++ Nil 2-4 
epi 
cells 
Left maxillary 
haziness – 
Left maxillary 
sinusitis 
Pain and 
rhinitis 
reduced AT 9,700 56 30 4 10 20 9.5 120 17 141 Nil Nil Occ. 
Pus 
cells 
16. 7049 Hariharan 
20/M 
Congestion 
sneezing 
rhinitis pain 
PNS present 
12.12.07 
6.2.08 
BT 9,000 57 38 5 5 11 12 80 20 140 Nil Nil Occ 
pus 
cells Frontal 
sinusitis 
All 
symptoms 
reduced AT 9,800 54 14 5 10 16 11 88 23 155 Nil Nil Few 
epi 
cell 
17. 861 Bhuvane 
shwari 45/F 
Rhinitis 
sneezing 
PNS pain 
present 
24.12.07 
14.2.07 
BT 8,800 60 33 7 10 15 9 95 18 135 Nil Nil Occ 
pus 
cells 
Normal study 
Symptoms 
moderately 
reduced AT 9,000 57 35 5 15 30 8.5 82 17 138 Nil Nil Few 
epi 
cells 
18. 1047 Lavanya  
26/F 
Pain PNS 
sneezing 
and 
congestion 
present 
25.12.07 
21.2.08 
BT 8,800 60 33 7 15 32 9 73 19 150 Nil Nil Occ 
pus 
cells 
Haziness 
noted in 
bilateral 
maxillary 
sinuses – 
Bilateral 
maxillary 
sinusitis 
PNS pain 
present 
sneezing 
and 
congestion 
reduced 
AT 9,500 59 30 4 10 15 9 85 17 135 Nil Nil Occ 
pus 
cells 
Sl. 
No. 
OP 
No. 
Name Age 
/Sex 
Complaint Duration BT 
AT 
Investigation Result 
Blood Se Urine Xray 
PNS TC 
cell/cu.mm 
DC % ESR  Hb Sug Urea CL Sug Alb Dep 
P L E ½ 1 
19. 2097 Sudha 
51/F 
Sneezing 
and 
congestion 
present 
27.12.07 
14.2.08 
BT 9,800 57 38 5 5 11 12 73 17 149 Nil Nil Occ 
pus 
cells 
Bilateral 
maxillary 
haziness and 
turbinate 
thickening, 
maxillary 
sinusitis 
Sneezing 
and 
congestion 
reduced 
AT 9,500 54 30 4 2 4 11 82 18 135 Nil Nil Occ 
pus 
cells 
20. 4232 Silambarasan 
20/M 
Sneezing 
rhinitis 
congestion 
present 
3.1.08 
27.3.08 
BT 9,000 58 36 6 10 42 11 135 28 115 Nil Nil Occ 
pus 
cells 
Right frontal 
haziness – 
Frontal 
sinusitis 
Rhinitis and 
congestion 
absent 
sneezing 
present 
AT 8,900 52 30 4 10 15 10 112 20 135 Nil Nil Occ 
pus 
cells 
21. 5457 Jayaraman 
27/M 
Congestion 
Rhinitis pain 
PNS present 
7.1.08 
4.3.08 
BT 9,900 39 28 7 2 13 12 116 25 145 Nil Nil Occ 
pus 
cells 
Left maxillary 
haziness – 
Left maxillary 
sinusitis 
Rhinitis 
present 
congestion 
relieved 
AT 9,800 42 30 4 10 15 8 125 20 150 Nil Nil Occ 
pus 
cells 
22. 5621 Subesh 
31/M 
Sneezing 
pain PNS 
present 
7.1.08 
26.2.08 
BT 9,300 55 34 4 11 20 9 135 16 157 Nil Nil Occ 
pus 
cells 
Bilateral 
maxillary 
haziness – 
Bilateral 
maxillary 
sinusitis 
Pain and 
sneezing 
reduced AT 9,400 57 38 5 10 15 10.5 116 19 160 Nil Nil Occ 
pus 
cells 
23. 6144 Premnath 
27/M 
PNS pain 
sneezing 
rhinitis  
9.1.08 
20.3.08 
BT 9,800 57 38 5 5 11 12 73 17 149 Nil Nil Occ 
pus 
cells 
Left maxillary 
haziness – 
Left maxillary 
sinusitis 
Pain rhinitis 
reduced AT 9,500 54 30 4 2 3 11 110 18 152 Nil Nil Few 
epi 
cells 
24. 7776 Arunkumar 
21/M 
Pain PNS 
congestion 
sneezing 
present 
14.1.08 
15.3.08 
BT 9,400 58 35 7 2 3 12 105 28 159 Nil Nil Occ 
pus 
cells 
Bilateral 
maxillary 
haziness – 
maxillary 
sinusitis 
Pain 
sneezing 
reduced 
congestion 
present 
AT 9,200 60 30 4 11 30 11.5 92 25 147 Nil Nil Occ 
pus 
cells 
Sl. 
No. 
OP 
No. 
Name Age 
/Sex 
Complaint Duration BT 
AT 
Investigation Result 
Blood Se Urine Xray 
PNS TC 
cell/cu.mm 
DC % ESR  Hb Sug Urea CL Sug Alb Dep 
P L E ½ 1 
25. 9584 Perumal  
47/M 
Rhinitis 
sneezing 
congestion 
pain PNS 
present 
21.1.08 
25.3.08 
BT 9,500 58 36 6 12 25 11 108 23 172 Nil Nil Occ 
pus 
cells 
Frontal and 
maxillary 
haziness, 
frontal and 
maxillary 
sinusitis 
Nasal 
congestion 
reduced AT 9,300 50 29 4 10 15 9 95 20 172 Nil Nil Occ 
pus 
cells 
26. 459 Thulasi 
45/F 
Pain PNS 
sneezing 
congestion 
present 
23.1.08 
21.2.08 
BT 10,600 62 32 6 20 44 9.5 87 25 179 Nil Nil Occ 
pus 
cells 
Normal study 
Pain and 
congestion 
reduced AT 9,900 60 24 4 10 20 10 95 20 150 Nil Nil Occ 
pus 
cells 
27. 655 Devi 
43/F 
Rhinitis 
sneezing 
PNS pain 
and 
congestion 
present 
24.1.08 
13.3.08 
BT 9,700 55 41 4 42 80 10.5 91 27 181 Nil Nil Few 
epi  
cells Bilateral 
maxillary 
sinusitis 
Pain reduce 
rhinitis 
present AT 9,800 51 42 5 15 25 10 98 22 153 Nil Nil Occ 
pus 
cells 
28. 1211 Thenmozhi 
30/F 
Rhinitis 
sneezing 
nasal 
congestion 
PNS pain 
present 
25.1.08 
31.3.08 
BT 9,700 59 34 7 15 34 10 88 18 157 Nil Nil Few 
pus 
cells 
Bilateral 
maxillary 
haziness – 
bilateral 
maxillary 
sinusitis 
Nasal 
congestion 
sneezing 
reduced 
AT 9,400 52 44 4 25 54 10 89 18 155 Nil Nil Few 
pus 
cells 
29. 2700 Selvam 
33/M 
Nasal 
congestion 
sneezing 
present 
24.3.08 
28.1.08 
BT 9,200 58 36 6 2 3 11.5 83 21 169 Nil Nil Few 
pus 
cells 
Frontal 
maxillary 
haziness – 
Frontal and 
maxillary 
sinusitis 
Congestion 
and 
sneezing 
reduced 
AT 9,700 59 36 5 2 5 11 91 21 166 Nil Nil Occ 
pus 
cells 
30. 2608 Nasiburahman 
66/M 
Rhinitis 
sneezing 
PNS pain 
congestion 
present 
29.1.08 
25.3.08 
BT 9,400 59 35 6 2 3 11 266 28 193 ++ Nil Few 
epi 
cells 
Right maxillary 
haziness – 
Maxillary 
sinusitis 
All 
symptoms 
relieved AT 9,500 36 32 4 10 15 10 200 26 190 ++ Nil Occ 
pus 
cells 
Sl. 
No. 
OP 
No. 
Name Age 
/Sex 
Complaint Duration BT 
AT 
Investigation Result 
Blood Se Urine Xray 
PNS TC 
cell/cu.mm 
DC % ESR  Hb Sug Urea CL Sug Alb Dep 
P L E ½ 1 
31. 2997 Karpagam 
59/M 
Rhinitis 
congestion 
sneezing 
PNS pain 
present 
30.1.08 
21.2.08 
BT 9,400 57 38 5 11 20 10.5 200 24 193 Nil Nil Occ. 
pus 
cells 
Normal study 
Rhinitis 
Nasal 
congestion 
reduced 
sneezing 
present 
AT 9,600 51 36 4 10 20 9 145 19 185 Nil Nil Occ 
pus 
cells 
32. 3770 Karuna 
Moorthi  52/M 
Rhinitis 
sneezing 
nasal 
congestion 
present 
31.1.08 
26.3.08 
BT 9,800 60 34 6 4 9 12 132 27 196 Nil Nil 2-4  
pus 
cell 
Left frontal 
haziness – 
Left frontal 
sinusitis 
All 
symptoms 
relieved AT 9,700 56 32 4 5 15 12.5 110 23 154 Nil Nil Few 
pus 
cells 
33. 3842 Sudha 
40/F 
Pain PNS 
sneezing 
nasal 
congestion 
present 
1.2.08 
21.3.08 
BT 9,900 52 33 6 10 15 10 95 18 140 Nil Nil Occ 
pus 
cells 
Bilateral 
maxillary 
haziness – 
Bilateral 
maxillary 
sinusitis 
Symptoms 
relieved AT 9,400 49 29 5 5 10 9 90 16 137 Nil Nil Few 
pus 
cells 
34. 4680 Yasodha 
F/45 
Pain 
congestion 
sneezing 
aggravates 
in the  
morning 
4.2.08 
21.3.08 
BT 9,800 60 32 8 10 18 10.5 10.9 19 177 Nil Nil Few 
pus 
cells 
Left maxillary 
haziness – 
Left maxillary 
sinusitis 
Pain 
reduced 
sneezing 
present 
AT 9,500 59 30 6 10 15 9 95 15 153 Nil Nil Few 
pus 
cells 
35. 3987 Ravikumar 
M/43 
Congestion 
pain 
sneezing 
present 
2.2.08 
21.3.08 
BT 9,800 59 35 6 4 9 11 98 21 170 Nil Nil Occ. 
pus 
cells Bilateral 
maxillary 
sinusitis 
Pain and 
congestion 
reduced 
sneezing 
present 
AT 9,600 54 30 4 5 10 10.5 112 18 169 Nil Nil Occ. 
pus 
cells 
36. 8253 Malar 
F/31 
Congestion 
rhinitis and 
sneezing 
pain PNS 
present 
13.2.08 
26.3.08 
 
BT 9,000 60 33 7 15 40 9.5 81 18 160 Nil Nil Occ 
pus 
cells Normal study 
Congestion 
and 
sneezing 
present 
AT 9,200 62 35 4 10 20 10 110 17 153 Nil Nil Occ. 
pus 
cells 
Sl. 
No. 
OP 
No. 
Name Age 
/Sex 
Complaint Duration BT 
AT 
Investigation Result 
Blood Se Urine Xray 
PNS TC 
cell/cu.mm 
DC % ESR  Hb Sug Urea CL Sug Alb Dep 
P L E ½ 1 
37. 9303 Balaji 
22/M 
Rhinitis and 
sneezing 
nasal 
congestion 
present  
16.2.08 
29.3.08 
BT 10,000 62 32 6 2 5 11 98 21 143 Nil Nil Occ 
pus 
cells 
Bilateral 
maxillary 
haziness -  
Maxillary 
sinusitis 
Rhinitis 
sneezing 
congestion 
present 
AT 9,900 53 30 4 15 20 10.5 102 18 132 Nil Nil Occ 
Pus 
Cells 
38. 4386 Selvi 
30/F 
Pain – PNS, 
Rhinitis and 
sneezing 
nasal 
congestion 
present 
29.2.08 
30.3.08 
BT 9,500 59 36 5 12 20 10.5 152 18 154 Nil Nil Few 
pus 
cells 
Normal study 
Congestion 
Pain, 
rhinitis and 
reduced 
sneezing 
present 
AT 9,700 54 32 4 10 20 11 110 20 142 Nil Nil Occ 
Pus 
cell 
39. 5977 Raguraj 
36/M 
Pain in the 
PNS 
sneezing 
and rhinitis 
congestion 
present 
11.4.08 
23.5.08 
 
BT 9,500 59 35 6 7 1 12 91 21 153 Nil Nil Occ 
pus 
cells 
Right maxillary 
haziness – 
Right maxillary  
sinusitis 
Pain 
sneezing 
and rhinitis 
reduced 
sneezing 
present 
AT 9,300 45 36 4 10 20 14 120 18 148 Nil Nil Occ 
pus 
cells  
40. 6368 Jayashankar 
23/M 
Nasal 
congestion 
and 
sneezing 
pain PNS 
present 
5.3.08 
18.4.08 
BT 9,600 58 36 6 2 5 11 110 18 137 Nil Nil 1 – 2 
epi 
cells Bilateral 
maxillary 
sinusitis 
Pain 
congestion 
reduced 
sneezing 
present 
AT 9,400 43 35 4 11 20 10 98 17 154 Nil Nil Occ. 
Pus 
cells 
 
 
 
BT - Before treatment    P - Polymorphs 
AT - After treatment     L - Lymphocytes 
TC - Total count cells / cu.mm   E - Eosinophils 
DC - Differential count    Sug - Blood sugar in mg/dl 
ESR - Erythrocyte sedimentation rate   Se CL - serum cholesterol in mg/dl 
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Sl. 
No 
OP 
No. 
Name Age 
/Sex Complaints Duration 
BT 
AT 
 Investigation Result 
Blood  Se Urine Motion 
TC 
cell/cu.mm 
DC % ESR 
Sug Urea CL Sug Alb Dep Ova /cyst 
Occ. 
Blood P L E ½ 1 
1. 9876 Sargunam 
39/F 
Pallor 
tiredness, 
loss of 
appetite 
present 
19.1.0.07 
1.12.07 
BT 10,400 66 30 4 10 24 120 25 168 Nil Nil Occ. 
pus 
cells 
Nil Nil 
All 3 
symptoms 
relieved AT 10,600 69 29 5 15 30 114 18 145 Nil Nil Occ. 
pus 
cells 
Nil Nil 
2. 2439 Yasodha 
59/F 
Fatigue and 
loss of 
appetite 
present  
29.10.07 
13.12.07 
BT 9,100 48 46 6 10 18 120 19 143 Nil Nil Occ. 
pus 
cells 
Nil Nil Appetite 
developed 
tiredness 
absent 
AT 9,000 52 49 6 10 20 110 18 153 Nil Nil Occ. 
pus 
cells 
Nil Nil 
3. 2989 Kamini 
18/F 
Loss of 
appetite, 
pallor 
present 
31.10.07 
18.12.07 
BT 9,100 58 36 6 10 22 98 16 170 Nil Nil Occ. 
pus 
cells 
Nil Nil Loss of 
appetite and 
pallor 
present 
AT 9,000 62 32 6 5 15 92 21 152 Nil Nil Occ. 
pus 
cells 
Nil Nil 
4. 3597 Naveena 
19/F 
Fatigue and 
loss of  
appetite 
present 
2.11.07 
13.12.07 
BT 9,500 58 36 4 12 25 111 18 132 Nil Nil Occ  
pus 
cells 
Nil Nil Appetite 
developed 
tiredness 
reduced 
AT 9,800 69 42 4 10 20 115 26 143 Nil Nil 1-2 
epi 
cells 
Nil Nil 
5. 6133 Anuradha 
19/F 
Pallor,  
Tiredness 
present  
12.11.07 
4.12.07 
BT 9,700 59 34 4 15 34 88 18 157 Nil Nil Occ. 
Pus 
Cells 
Nil Nil 
Fatigue and 
pallor 
reduced AT 9,600 49 42 5 20 35 95 16 145 Nil Nil Few 
Pus 
cells 
Nil Nil 
Sl. 
No 
OP 
No. 
Name Age 
/Sex Complaints Duration 
BT 
AT 
 Investigation Result 
Blood  Se Urine Motion 
TC 
cell/cu.mm 
DC % ESR 
Sug Urea CL Sug Alb Dep Ova /cyst 
Occ. 
Blood P L E ½ 1 
6. 4423 Sekar 
60/M 
Fatigue loss 
of appetite 
present 
5.11.07 
25.12.07 
BT 9,800 54 41 5 10 20 88 23 155 Nil Nil Occ. 
Pus 
Cells 
Nil Nil Appetite 
developed 
fatigue 
absent 
AT 9,900 59 48 6 10 15 90 18 147 Nil Nil Few 
Pus 
Cells 
Nil Nil 
7. 7665 Thangam 
22/F 
Fatigue loss 
of appetite 
present 
16.11.07 
26.12.07 
BT 9,900 60 33 4 15 32 112 23 146 Nil Nil 1-2 
epi 
Cell 
Nil 
 
Nil 
 Appetite 
developed 
fatigue 
present 
AT 9,800 49 32 5 10 15 107 25 132 Nil Nil 3-4 
pus 
cells 
Nil Nil 
8. 7663 Subbulakshmi 
55/F 
Fatigue 
pallor 
present 
16.11.07 
27.12.07 
BT 9,000 60 33 4 15 30 81 18 160 Nil Nil Few 
epi 
cells 
Nil Nil Tiredness 
reduced 
appetite 
developed 
AT 8,990 62 35 5 20 30 123 16 155 Nil Nil Occ. 
pus 
cells 
Nil Nil 
9. 8147 Leela 
23/F 
Loss of 
appetite, 
fatigue pallor 
present 
17.11.07 
27.12.07 
BT 9,500 58 36 5 12 25 110 18 147 Nil Nil Occ.  
pus 
cells 
Nil Nil 
All 
symptoms 
reduced AT 9,200 46 32 4 10 25 98 23 135 Nil Nil Occ. 
pus 
cells 
Nil Nil 
10. 8267 Ramesh 
50/M 
Loss of 
appetite 
pallor 
tiredness 
present 
17.11.07 
10.1.08 
BT 10,000 62 32 6 2 5 90 21 157 Nil Nil Occ. 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,500 59 35 6 4 9 112 19 142 Nil Nil Occ. 
pus 
cells 
Nil Nil 
11. 8269 Kamakshi 
25/F 
Loss of 
appetite 
pallor 
tiredness 
present 
7.11.07 
3.1.08 
BT 9,000 54 41 5 5 11 88 23 155 Nil Nil Occ. 
pus 
cells 
Nil Nil Pallor 
present 
fatigue 
appetite 
improved 
AT 9,800 57 38 5 10 16 91 18 145 Nil Nil 1-2 
epi 
cells 
Nil Nil 
 
Sl. 
No 
OP 
No. 
Name Age 
/Sex Complaints Duration 
BT 
AT 
 Investigation Result 
Blood  Se Urine Motion 
TC 
cell/cu.mm 
DC % ESR 
Sug Urea CL Sug Alb Dep Ova /cyst 
Occ. 
Blood P L E ½ 1 
12. 9104 Jaya 23/F Pallor 
fatigue loss 
of appetite 
present 
20.11.07 BT 9,200 58 36 6 2 10 83 21 169 Nil Nil Occ. 
pus 
cells 
Nil Nil Fatigue and 
loss of 
appetite 
reduced 
pallor 
present 
AT 9,700 59 36 5 2 5 101 16 145 Nil Nil Occ. 
pus 
cells 
Nil Nil 
13. 956 Agalya  
15/F 
Loss of 
appetite 
pallor 
tiredness 
present 
26.11.07 
15.1.08 
BT 9,700 59 34 6 15 34 88 18 157 Nil Nil Occ 
pus 
cells 
Nil Nil 
All 3 
symptoms 
improved AT 9,600 50 33 5 10 20 105 23 163 Nil Nil Occ 
pus 
cells 
Nil Nil 
14. 3190 Sivamani 
30/M 
Loss of 
appetite 
pallor 
tiredness 
present 
1.12.07 
17.1.08 
BT 9,300 57 39 5 12 20 125 17 147 Nil Nil Occ 
pus 
cells 
Nil Nil 
Pallor 
present 
fatigue and 
loss appetite 
reduced 
AT 9,200 59 40 4 10 20 113 19 132 Nil Nil Occ 
pus 
cells 
Nil Nil 
15. 1973 Uma 
17/F 
Loss of 
appetite 
tiredness 
present 
28.11.07 
18.1.08 
BT 8,900 49 32 6 10 35 130 22 159 Nil Nil Occ 
pus 
cells 
Nil Nil 
Appetite 
improved 
fatigue 
present 
AT 9,000 52 45 5 10 20 117 25 135 Nil Nil 1-2 
epi 
cells 
Nil Nil 
16. 3730 Kasthuri  
45/F 
Pallor 
tiredness 
present 
3.12.07 
24.1.08 
BT 10,200 64 29 5 2 5 83 28 169 Nil Nil Occ 
pus 
cells 
Nil Nil 
Symptoms 
reduced AT 10,300 60 32 5 10 20 90 19 157 Nil Nil Occ 
pus 
cells 
Nil Nil 
17. 3964 Manju  
12/F 
Loss of 
appetite 
tiredness 
present 
4.12.07 
24.10.08 
BT 9,400 47 48 5 5 9 85 17 132 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Good 
appetite 
present 
tiredness 
reduced 
AT 9,300 45 40 4 10 15 89 19 139 Nil Nil Occ 
pus 
cells 
Nil Nil 
Sl. 
No 
OP 
No. 
Name Age 
/Sex Complaints Duration 
BT 
AT 
 Investigation Result 
Blood  Se Urine Motion 
TC 
cell/cu.mm 
DC % ESR 
Sug Urea CL Sug Alb Dep Ova /cyst 
Occ. 
Blood P L E ½ 1 
18. 9126 Raguraj 
64/M 
Loss of 
appetite 
pallor 
tiredness 
present 
18.12.07 
27.03.08 
BT 9,800 58 36 6 12 25 109 23 172 Nil Nil Occ 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,900 59 39 5 10 15 120 17 157 Nil Nil Occ 
pus 
cells 
Nil Nil 
19. 9515 Loganathan 
85/M 
Loss of 
appetite 
pallor 
tiredness 
present 
20.12.07 
7.2.08 
BT 10,000 62 32 6 20 44 87 25 179 Nil Nil Occ 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,900 60 30 5 10 20 108 20 150 Nil Nil Occ 
pus 
cells 
Nil Nil 
20. 166 Pushpa 
38/F 
Loss of 
appetite 
tiredness 
present 
22.12.07 
4.3.08 
BT 9,200 58 36 6 10 22 120 18 162 Nil Nil Occ 
pus 
cells 
Nil Nil 
Loss of 
appetite and 
tiredness 
present 
AT 9,100 57 30 5 10 15 114 23 147 Nil Nil Occ 
pus 
cells 
Nil Nil 
21. 1917 Janani 
15/F 
Loss of 
appetite 
pallor 
tiredness 
present 
27.12.07 
14.2.08 
BT 9,000 48 46 6 10 18 119 16 136 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Pallor 
reduced 
appetite 
fatigue 
present 
AT 9,200 52 49 5 5 15 97 23 149 Nil Nil Occ. 
pus 
cells 
Nil Nil 
22. 7098 Jothi 
36/F 
Loss of 
appetite 
pallor 
tiredness 
present 
11.10.08 
1.3.08 
BT 8,700 55 41 4 34 60 106 19 165 Nil Nil Few 
epi 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,000 56 45 5 20 36 112 17 153 Nil Nil 1-2 
epi 
cells 
Nil Nil 
23. 872 Dhanam 
43/F 
Loss of 
appetite 
pallor 
tiredness 
present 
18.1.08 
31.3.08 
BT 10,600 66 30 4 10 24 120 25 120 Nil Nil Occ 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 10,300 60 39 4 5 15 119 20 107 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Sl. 
No 
OP 
No. 
Name Age 
/Sex Complaints Duration 
BT 
AT 
 Investigation Result 
Blood  Se Urine Motion 
TC 
cell/cu.mm 
DC % ESR 
Sug Urea CL Sug Alb Dep Ova /cyst 
Occ. 
Blood P L E ½ 1 
24. 9889 Shanmugam 
70/M 
Loss of 
appetite 
pallor 
tiredness 
present 
22.1.108 
10.3.08 
BT 8,700 51 44 5 4 9 93 25 180 Nil Nil Occ. 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,000 49 32 5 10 15 87 19 173 Nil Nil Occ. 
pus 
cells 
Nil Nil 
25. 9965 Bakianathan 
65/M 
Loss of 
appetite 
pallor 
tiredness 
present 
22.1.08 
11.3.08 
BT 9,200 58 36 6 10 22 103 20 158 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Pallor and 
fatigue 
present 
appetite 
improved 
AT 9,000 55 32 4 10 15 115 22 145 Nil Nil Occ. 
pus 
cells 
Nil Nil 
26. 353 Dhesamma 
35/F 
Loss of 
appetite 
tiredness 
present 
23.1.08 
13.3.08 
BT 9,000 57 38 5 12 20 78 23 170 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Appetite 
improved 
tiredness 
present 
AT 9,100 59 39 6 12 24 95 17 165 Nil Nil Occ. 
pus 
cells 
Nil Nil 
27. 771 Gayathri 
19/F 
Pallor 
tiredness 
present 
24.1.08 
6.3.08 
BT 9,200 54 40 6 25 54 70 17 149 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Both 
symptoms 
reduced AT 9,000 54 32 6 20 30 90 20 153 Nil Nil Occ. 
pus 
cells 
Nil Nil 
28. 796 Banurega 
36/F 
Loss of 
appetite 
pallor 
present 
24.1.08 
27.3.08 
BT 9,900 52 41 6 11 20 91 18 177 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Pallor 
present 
appetite 
improved 
AT 9,700 56 42 5 10 25 83 20 163 Nil Nil Occ. 
pus 
cells 
Nil Nil 
29. 773 Sellammal 
55/F 
Loss of 
appetite 
pallor 
tiredness 
present 
24.1.08 
13.3.08 
BT 10,000 63 31 6 25 54 99 27 183 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Appetite 
improved 
fatigue and 
pallor 
present 
AT 9,900 60 32 5 20 35 103 19 174 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Sl. 
No 
OP 
No. 
Name Age 
/Sex Complaints Duration 
BT 
AT 
 Investigation Result 
Blood  Se Urine Motion 
TC 
cell/cu.mm 
DC % ESR 
Sug Urea CL Sug Alb Dep Ova /cyst 
Occ. 
Blood P L E ½ 1 
30. 1646 Kamalammal 
60/F 
Loss of 
appetite 
pallor 
present 
27.1.08 
6.3.08 
BT 10,000 57 29 3
4 
20 46 112 20 163 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Pallor 
present 
appetite 
improved 
AT 10,100 49 32 6 20 35 115 17 157 Nil Nil Occ. 
pus 
cells 
Nil Nil 
31. 2668 Meenakshi 
65/F 
Loss of 
appetite 
pallor 
tiredness 
present 
29.1.08 
31.3.08 
BT 9,800 57 39 5 5 11 74 17 150 Nil Nil Occ. 
pus 
cells 
Nil Nil Fatigue 
persists 
appetite 
improved  
pallor 
reduced 
AT 9,700 59 38 3 10 20 112 20 135 Nil Nil Occ. 
pus 
cells 
Nil Nil 
32. 45 Suharbanu 
28/F 
Loss of 
appetite 
pallor 
tiredness 
present 
22.1.08 
13.3.08 
BT 9,300 57 38 5 12 20 99 19 158 Nil Nil Occ. 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,100 59 32 4 12 24 102 21 154 Nil Nil Occ. 
pus 
cells 
Nil Nil 
33. 3432 Dhayalan 
35/M 
Loss of 
appetite 
pallor 
tiredness 
present 
31.1.08 
31.3.08 
BT 8,700 55 41 4 2 5 100 21 167 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Appetite 
improved 
pallor and 
fatigue 
reduced 
AT 9,000 56 42 5 5 10 97 17 152 Nil Nil Occ. 
pus 
cells 
Nil Nil 
34. 545 Sasikala 
65/F 
Loss of 
appetite 
pallor 
tiredness 
present 
31.1.08 
20.3.08 
BT 9,200 58 34 6 12 25 92 22 143 Nil Nil Occ. 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,100 60 35 5 10 20 88 19 135 Nil Nil Occ. 
pus 
cells 
Nil Nil 
35. 3758 Kasiamma 
65/F 
Pallor 
tiredness 
present 
1.2.08 
27.3.08 
BT 9,500 59 35 4 20 30 85 17 140 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Pallor 
present 
tiredness 
reduced 
AT 9,400 47 32 4 10 15 99 21 152 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Sl. 
No 
OP 
No. 
Name Age 
/Sex Complaints Duration 
BT 
AT 
 Investigation Result 
Blood  Se Urine Motion 
TC 
cell/cu.mm 
DC % ESR 
Sug Urea CL Sug Alb Dep Ova /cyst 
Occ. 
Blood P L E ½ 1 
36. 8975 Bhavani 
35/M 
Loss of 
appetite 
pallor 
tiredness 
present 
18.2.08 
1.4.08 
 
BT 8,700 53 43 4
2 
15 34 87 18 168 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Fatigue and 
Pallor 
reduced 
tiredness 
present 
AT 9,100 52 49 5 10 15 94 23 172 Nil Nil Occ. 
pus 
cells 
Nil Nil 
37. 6728 Saraswathi 
40/F 
Loss of 
appetite 
tiredness 
present 
6.3.08 
9.4.08 
BT 10,200 64 29 6 30 54 83 28 179 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Loss of 
appetite 
present 
fatigue 
reduced 
AT 9,600 53 35 4 10 15 105 25 145 Nil Nil Occ. 
pus 
cells 
Nil Nil 
38. 6003 Latha  
42/F 
Loss of 
appetite 
tiredness 
present 
4.3.08 
10.4.08 
BT 9,700 55 41 4 15 20 135 19 147 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Fatigue 
present 
appetite 
improved 
AT 8,900 49 39 5 20 40 142 22 165 Nil Nil Occ. 
pus 
cells 
Nil Nil 
39. 6776 Srinidhi 
28/F 
Loss of 
appetite 
pallor 
tiredness 
present 
6.3.08 
12.4.08 
BT 9,700 59 33 7 15 30 87 19 153 Nil Nil Occ. 
pus 
cells 
Nil Nil 
Loss of 
appetite 
present 
tiredness 
reduced 
AT 8,900 49 39 5 20 40 142 22 165 Nil Nil Occ. 
pus 
cells 
Nil Nil 
40. 3603 Priya 
18/F 
Loss of 
appetite 
pallor 
tiredness 
present 
27.2.08 
12.4.08 
BT 9,000 57 36 7 20 38 152 19 153 Nil Nil Occ. 
pus 
cells 
Nil Nil 
All 3 
symptoms 
reduced AT 9,200 49 32 5 15 25 147 22 147 Nil Nil Occ. 
pus 
cells 
Nil Nil 
  
BT - Before treatment    P - Polymorphs 
AT - After treatment     L - Lymphocytes 
TC - Total count cells / cu.mm   E - Eosinophils 
DC - Differential count    Sug - Blood sugar in mg/dl 
ESR - Erythrocyte sedimentation rate   Se CL - serum cholesterol in mg/dl 
 
